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Les norovirus (genre Norovirus, famille Caliciviridae) représentent la cause principale de 
gastro-entérite sporadique et épidémique non bactérienne chez l'homme au niveau mondial. La 
recombinaison et l'accumulation de mutations ponctuelles sont des mécanismes clés de l'évolution et de 
la diversité des norovirus; de plus en plus de preuves indiquent que la recombinaison façonne la 
pathogenèse et l'aptitude réplicative des norovirus et entraîne l'évolution de souche émergentes de 
norovirus humains. 
La compréhension générale de la biologie des norovirus humains et en particulier de leur 
recombinaison est peu connue par rapport à celle d'autres virus, en raison, entre autres, de la difficulté 
que représente l’étude in vitro des norovirus humains. Malgré des avancées spectaculaires au niveau de 
l’étude in vivo et in vitro des norovirus humains, des questions importantes restent sans réponse en raison 
des limites techniques de ces systèmes expérimentaux. L’étude du norovirus murin, qui est 
génétiquement et biologiquement apparenté aux norovirus humains, combine plusieurs avantages, à 
savoir :  une infection expérimentale in vivo relativement aisée sur un type d'hôte propice, d'une culture 
in vitro efficace et reproductible, et d’une large disponibilité d'outils de manipulation génétique. Il reste 
ainsi le modèle de choix pour l’étude de norovirus. 
Cette thèse étudie les différents points de contrôle de la recombinaison: la co-infection de l'hôte, 
la co-infection de la cellule cible, la recombinaison en tant que processus et la sélection fonctionnelle 
des souches résultantes sont examinées. La thèse discute aussi qui les facteurs qui les favorisent ou le 
défavorisent. 
L'article de revue «Norovirus recombinants: recurrent in the field, recalcitrant in the lab – a 
scoping review of recombination and recombinant types of noroviruses» (Ludwig-Begall et al., 2018) 
donne un aperçu complet de la recombinaison chez les norovirus et de son rôle dans leur évolution 
moléculaire. De plus, elle identifie les inconnues concernant les processus se déroulant avant et après la 
recombinaison stricto sensu; dans l'étude de la co-infection cellulaire à la sélection fonctionnelle, les 
études expérimentales 1 et 2 fournissent de nouvelles informations sur ces étapes cruciales. 
In vivo, la co-infection unicellulaire synchrone par plusieurs virus est susceptible d'être un 
événement rare et les infections secondaires retardées sont plus probables. L'étude 1 détermine l'effet 
d'une séparation temporelle des infections in vitro avec les deux souches parentales de norovirus murins 
homologues MNV-1 WU20 et CW1 et leur impact sur la composition des populations de norovirus 
murins. En résumé, WU20 et CW1 ont été inoculés, soit de manière simultanée sur des monocouches 
de cellules macrophages murines (co-infection), soit en différé (surinfection avec des titres variables de 
CW1, d'une demi-heure à 24 heures de délai). Vingt-quatre heures après la co- ou surinfection initiale, 
Abstract 
3 
la quantification du nombre de copies génomiques et du criblage des virus de descendance infectieuses 
prélevés sur plaque ont démontré une prédominance dépendante du temps pour une primo-infection avec 
WU20 dans la majorité des nouvelles générations. Nos résultats indiquent qu'un intervalle de temps 
d'une à deux heures entre deux infections consécutives à norovirus permet l'établissement d'une barrière 
qui réduit ou empêche la surinfection; ceci représente la première démonstration d'interférence virale 
temporelle pour les norovirus et a des conséquences claires sur la compréhension de l'épidémiologie des 
norovirus, l'évaluation des risques et potentiellement sur le traitement. 
L'étude 2 examine les processus ayant lieu directement après la recombinaison et vise à 
caractériser la capacité d'adaptation du norovirus murin recombinant WU20-CW1 précédemment généré 
in vitro, RecMNV, et examine ainsi comment l'accumulation de mutations ponctuelles à travers des 
passages viraux successifs peut compenser les pertes de capacité réplicative subies lors de la 
recombinaison. En comparant l'aptitude réplicative (replicative fitness) et les caractéristiques génétiques 
des descendants de RecMNV aux stades précoces et tardifs d'une expérience d'adaptation, le 
rétablissement de l'aptitude réplicative (replicative fitness) du recombinant a été démontré avant et après 
le passage in vitro en série. Les profils phénotypiques ont été associés à des modifications génétiques 
au niveau de la population. Pour étudier l'effet des changements génomiques séparés ou non au sein d'un 
norovirus murin infectieux chimérique, obtenu artificiellement, des mutations ont été introduites dans 
un ADNc recombinant WU20-CW1 en vue d’obtenir une récupération génétique inverse basée sur 
l'ADN. Cette expérience a prouvé que la perte de l’aptitude réplicative (replicative fitness) de RecMNV 
était ainsi liée à une mutation C7245T et à une troncature de la protéine de capside mineure (cadre de 
lecture ouvert 3) fonctionnelle; les effets compensatoires individuels et cumulatifs d'une mutation 
synonyme au niveau de la protéine majeure de capside (cadre de lecture ouvert 2) et de deux mutations 
non synonymes de la protéine non structurale 1/2 (cadre de lecture ouvert 1) acquises au cours de cycles 
successifs de réplication in vitro ont été démontrés, suggérant que les interactions entre les protéines 
virales et / ou les structures secondaires de l'ARN des cadres de lecture ouverts différents peuvent jouer 
un rôle dans la régulation de l'aptitude réplicative (replicative fitness) après recombinaison. 
Cette thèse sert à fournir un aperçu des points critiques affectant le processus de recombinaison 
et, via l’étude de l'exclusion de la surinfection et de la sélection fonctionnelle, fournit de nouvelles 




Noroviruses (genus Norovirus, family Caliciviridae) are recognised as the major global cause 
of sporadic and epidemic non-bacterial gastroenteritis in humans. Recombination and the accumulation 
of point mutations are key mechanisms in the evolution and diversity of noroviruses; increasing evidence 
indicates that recombination shapes norovirus pathogenesis and fitness and drives the evolution of 
emerging human norovirus strains.  
The understanding of human norovirus biology in general and norovirus recombination in 
particular has lagged behind that of other viruses due to the difficulties historically associated with 
robust in vitro human norovirus propagation. While recently developed in vivo and in vitro human 
norovirus assays have provided invaluable tools to dissect the norovirus life cycle, significant questions 
remain unanswered due to the technical limitations of many of these experimental systems. The 
genetically and biologically closely related murine norovirus combines the advantages of easy in vivo 
infection of a genetically tractable native host, efficient and robust in vitro culture, and availability of 
tools for genetic manipulation and thus remains the model of choice for many norovirus studies. 
In the context of this thesis, the various norovirus recombination checkpoints, namely host 
coinfection, single cell coinfection, recombination, and functional selection, are examined and their 
drivers and constraints are discussed.  
 The review “Norovirus recombinants: recurrent in the field, recalcitrant in the lab – a scoping 
review of recombination and recombinant types of noroviruses” (Ludwig-Begall et al., 2018) provides 
a comprehensive overview of norovirus recombination and its role in norovirus molecular evolution and 
identifies knowledge gaps pertaining to prerequisite processes both directly prior to and post actual 
recombination in sensu stricto; in investigating conditions governing cell coinfection and functional 
selection, respectively, experimental studies 1 and 2 provide novel insights into these crucial steps.  
In vivo, synchronous single-cell coinfection by multiple viruses, the ultimate prerequisite to viral 
recombination, is likely to be a rare event and delayed secondary infections are a more probable 
occurrence. Study 1 determines the effect of a temporal separation of in vitro infections with the two 
homologous parental murine norovirus strains MNV-1 WU20 and CW1 on the composition of murine 
norovirus populations. WU20 and CW1 were either synchronously inoculated onto murine macrophage 
cell monolayers (coinfection) or asynchronously applied (superinfection with varying titres of CW1 at 
half-hour to 24-hour delays). Twenty-four hours after initial co- or superinfection, quantification of 
genomic copy numbers and discriminative screening of plaque picked infectious progeny viruses 
demonstrated a time-dependent predominance of primary infecting WU20 in the majority of viral 
progenies. Our results indicate that a time interval from one to two hours onwards between two 
Abstract 
5 
consecutive norovirus infections allows establishment of a barrier that reduces or prevents super-
infection; this first demonstration of time-dependent viral interference for noroviruses has clear 
implications for norovirus epidemiology, risk assessment, and potentially treatment. 
Study 2 examines the processes directly following recombination and aims to characterise the 
adaptive capacity of previously in vitro-generated WU20-CW1 recombinant murine norovirus 
RecMNV, thus investigating how the accumulation of point mutations through successive viral 
passaging may compensate for initial replicative fitness losses incurred during deleterious 
recombination processes. By comparing the replicative fitness and genetic characteristics of RecMNV 
progenies at early and late stages of an adaptation experiment, replicative fitness regain of the 
recombinant was demonstrated between viral progenies prior to and post serial in vitro passaging and 
observable phenotypic profiles of viral fitness were associated to population-level genetic modifications. 
To investigate the effect of genomic changes separately and in combination in the context of an 
infectious lab-generated inter-murine norovirus chimera, mutations were introduced into a recombinant 
WU20-CW1 cDNA for subsequent DNA-based reverse genetics recovery. Fitness loss of RecMNV was 
thus linked to a C7245T mutation and functional minor capsid protein (open reading frame 3) truncation; 
individual and cumulative compensatory effects of one synonymous major capsid protein (open reading 
frame 2) and two non-synonymous non-structural protein 1/2 (open reading frame 1) consensus-level 
mutations acquired during successive rounds of in vitro replication were demonstrated, suggesting that 
interactions of viral proteins and/or RNA secondary structures of different open reading frames may 
play a role in the regulation of replicative fitness after a recombination event. This in vitro proof-of-
concept study thus simulates successful adaptation (genetic drift) of a nascent norovirus after 
recombination (genetic shift) and serves to conceptualise how the emergence of recombinant human 
norovirus field strains, held to represent an adapted and functionally selected subset of all generated 
recombinants, may be regulated by an interplay between the two evolutionary processes of 
recombination and point mutation accumulation. 
This thesis serves to provide a comprehensive overview of the recombination checkpoints to be 
bypassed and, in investigating both superinfection exclusion and functional selection, provides novel 
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Preamble 
Noroviruses  are recognised as the major global cause of sporadic and epidemic non-bacterial 
gastroenteritis in humans. Recombination and the accumulation of point mutations are key mechanisms 
in the evolution and diversity of noroviruses; increasing evidence indicates that recombination 
influences norovirus pathogenesis and fitness and contributes to the evolution of emerging human 
norovirus strains. Despite its importance, many aspects of norovirus recombination have hitherto 
remained unresolved. 
In the context of this thesis, the various norovirus recombination checkpoints, namely host 
coinfection, single cell coinfection, recombination, and functional selection, are examined and their 
drivers and constraints are discussed.  
The manuscript comprises four sections.  The first chapter of the introduction encompasses an 
overview of the various aspects of norovirus biology. This is followed by a detailed description of RNA 
virus evolutionary processes and the molecular evolution of noroviruses in chapter 2, which closes with 
a scoping review of recombination and recombinant types of noroviruses (published in Journal of 
General Virology). The thesis objectives are succeeded by the experimental section which is subdivided 
into two parts. Experimental Study 1 describes how the analysis of synchronous and asynchronous in 
vitro infections with homologous murine norovirus strains reveals time-dependent viral interference 
effects (published in Viruses). Experimental Study 2 focuses on the replicative fitness recuperation of a 
recombinant murine norovirus and describes the in vitro reciprocity of genetic shift and drift (published 
in Journal of General Virology). In the last section of this manuscript, the main results of this thesis are 







  Introduction 





1.1.1 The Caliciviridae family 
The Caliciviridae family of small, non-enveloped, positive sense, single-stranded RNA viruses 
derives its name from the Latin calix for chalice with reference to the cup-shaped depressions that 
commonly contour the virion surface of caliciviruses. The family is currently comprised of eleven 
approved genera, Norovirus, Sapovirus, Nebovirus, Recovirus, Lagovirus, Vesivirus, Valovirus, 
Bavovirus, Nacovirus, Minovirus and Salovirus (Figure 1),  which are distinguished based on over 60% 
amino acid sequence difference in the complete major capsid protein (VP1) sequence (Vinjé et al., 
2019).  
Caliciviridae infect a wide range of host species and cause a variety of mainly species-specific 
diseases (Desselberger, 2019). Within the seven genera of which members infect mammals, noroviruses 
and sapoviruses typically cause gastroenteritis of varying severity in their animal and human hosts (Oka 
et al., 2015; Robilotti et al., 2015; Scipioni et al., 2008a), while neboviruses and recoviruses are enteric 
pathogens of  cattle (Bridger et al., 1984) and rhesus macaques (Farkas, 2015; Farkas et al., 2008), 
respectively. Some lagoviruses and vesiviruses cause severe systemic infections in their mammalian 
hosts; pathogenic lagovirus infections provoke necrotic hepatitis and systemic haemorrhagic disease in 
lagomorphs (Abrantes et al., 2012; Le Pendu et al., 2017; Ohlinger et al., 1990; Wirblich et al., 1994), 
and vesivirus infections cause respiratory infections in cats (Radford et al., 2007), vesicular disease and 
foetal damage in swine, and vesicular exanthema and diseases of the reproductive system in marine 
mammals (Neill et al., 1995). The disease association of swine valoviruses remains unknown (L’Homme 
et al., 2009). Members of the two genera Bavovirus and Nacovirus have been associated with enteritis 
in poultry (Wolf et al., 2012); members of the two genera Minovirus and Salovirus infect various fish 
species (Mikalsen et al., 2014; Mor et al., 2017). 
 
1.1.2 The Norovirus genus 
The genetically diverse noroviruses (NoVs), which infect a broad range of mammalian hosts, 
derive their name from the city of Norwalk, Ohio, where an acute gastroenteritis outbreak in a school 
was caused by the prototypic Norwalk virus (Kapikian et al., 1972). In the early 2000s, classification 
into NoV genogroups and genotypes was initially based on amino acid sequence analysis of the complete 
VP1 capsid protein, with an amino acid divergence of 14.1% within a genotype and an adjusted cut-off 
threshold of a minimum of 15% pairwise difference proposed for classification of new genotypes (Vinjé 
et al., 2000; Zheng et al., 2006).  
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In 2013, the international Norovirus Classification Working Group (NCWG) put forth a 
proposal for a unified NoV nomenclature and genotyping, whereby NoVs were genetically classified 
into six established genogroups (GI–GVI), with a seventh proposed (GVII), and genogroups were 
further divided into at least 38 genotypes based on phylogenetic clustering of complete VP1 amino acid 
sequences (Kroneman et al., 2013; Vinjé, 2015); GII.4 strains were additionally subtyped into variants 
based both on phylogenetic clustering and on the condition of their having become epidemic in at least 
two separate geographical locations and were named according to year and location of the first full-
length capsid sequence in the public domain. To account for the common occurrence of recombination 
in the overlapping region between the first two of three open reading frames (ORF1/2) encoded by 
NoVs, a dual-nomenclature system based on complete capsid sequences in ORF2 and partial sequences 
of the RNA-dependent RNA polymerase (RdRp) region in ORF1 was established (Kroneman et al., 
2013). According to this nomenclature, e.g. “norovirus GII/Hu/FR/2004/GII.P12_GII.3/Paris23” 
designated a GII recombinant strain with known partial ORF1 RdRp type (GII, P type = 12)  and 
complete ORF2 (genotype = 3) sequences; “norovirus GII/Hu/FR/2004/GII.12/Paris25” denoted a strain 
with known capsid sequence (GII, genotype 12), but unidentified RdRp. Naming of “orphan” ORF1 
polymerase types, also known as “obligatory NoV recombinants” and designating known RdRp 
sequences lacking attributed capsid sequences but promiscuously associated with capsids of different 
genotypes, followed a preliminary alphabetical naming system (e.g. GI.Pa).  
Adhering to the established criteria for genotype attribution and numbering of complete capsid 
sequences, the prior classification was recently updated to encompass ten accepted genogroups (GI to 
GX) and 49 confirmed genotypes (Figure 1), as well as two tentative genogroups (GNA1 and GNA2) 
and three proposed genotypes (Chhabra et al., 2019). To more easily accommodate ORF1/2 
recombination of NoVs and to eliminate the necessity of the letter-based orphan ORF1 naming system, 
partial RdRp sequence clusters were grouped into eight confirmed and two tentative polymerase (P)-
groups as well as 60 accepted and 14 tentative P-types independently of the classification of their capsid 
genogroups or genotypes. Accordingly, nine VP1 genotypes in GI, 27 in GII, three in GIII, two each in 
GIV, GV and GVI, and one each in GVII to GX are currently recognised; of the P-types, 14 cluster in 
GI, 37 in GII, two in GIII, one in GIV, two each in GV and GVI, and one each in GVII and GX (Figure 
2). Separate phylogenetic clusters for both VP1 and partial RdRp sequences are confirmed according to 
the 2 × standard deviation criteria, which state that the average distance between all sequences within a 
newly identified cluster and its nearest established cluster, should not overlap within two standard 
deviations of each other (Chhabra et al., 2019). The previous dual typing nomenclature of norovirus 
strains was abandoned in favour of an updated version first listing the capsid genotype followed by the 
P-type between brackets (e.g. previous designation: GII.P12-GII.3; current designation: GII.3[P12]). 
For strains where ORFII and ORF1 amino acid sequences cluster in different genogroups, the 
designations are Genogroup.genotype[Pgroup.P-type] (e.g. previous designation: GVI.P1-GIV.2; 
current designation: GIV.2[GVI.P1] (Chhabra et al., 2019). 
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Genogroups GI, GII, GIV, GVIII and GIX (previously GII.15) infect humans and cause acute 
gastroenteritis (Chhabra et al., 2019; van Beek et al., 2018). Of these, viruses from the genotype GII.4 
are responsible for the majority of NoV outbreaks worldwide with novel pandemic GII.4 variants 
emerging every 2 to 3 years (Bruggink et al., 2017; de Graaf et al., 2016; Mathijs et al., 2011). Other 
species from which NoVs have been isolated include pigs (GII) (L’Homme et al., 2009), cattle and sheep 
(GIII) (Di Felice et al., 2016; Oliver et al., 2003; Scipioni et al., 2008a), rats and mice (GV) (Karst et 
al., 2003), dogs (GVI and GVII) (Mesquita et al., 2010) and bats (GX) (Wu et al., 2016). Tentative new 
genogroups GNA1 and GNA2 are detected in harbour porpoises (de Graaf et al., 2017a) and sea lions 
(Teng et al., 2018), respectively. The remarkable level of variability within the NoV genus reflects the 
high level of continuous viral evolution therein. 
  Introduction 
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In the following chapters, the focus of this thesis will be on both HuNoVs, the major aetiologic agents 
of global sporadic and epidemic viral gastroenteritis (Robilotti et al., 2015), and on the genetically and 
biologically closely related MuNoVs, which combine the advantages of efficient in vitro culture systems 
(Wobus et al., 2006, 2004) and availability of tools for genetic manipulation (Arias et al., 2012a; Yunus 
et al., 2010), and were used as a model for the NoV studies included in the context of this work. 
 
1.2 Genome organisation 
The linear, positive sense, single-stranded RNA genomes of NoVs are between 7.3 – 7.5 
kilobases (kb) in length (Thorne and Goodfellow, 2014); a subgenomic RNA identical to approximately 
the last 2.3 kb of the genome is found in viral particles and is expressed, at higher levels than the viral 
genomic RNA, in infected cells (Asanaka et al., 2005). The 5’ ends of NoV genomic and subgenomic 
RNA are linked to viral protein VPg (Goodfellow, 2011; Lee et al., 2018; Olspert et al., 2016), the 3’ 
ends are polyadenylated (Lambden et al., 1993). At their extremities, NoV genomes contain short 
untranslated regions (UTRs) (Bertolotti-Ciarlet et al., 2003) which contain evolutionarily conserved 
RNA secondary structures that extend into the coding regions and are repeated throughout the genome, 
playing functional roles for viral replication, translation and pathogenesis by binding viral and host 
factors (Simmonds et al., 2008); a highly conserved non-coding RNA stem-loop structure upstream of 
the start site for subgenomic RNA initiation at the overlap of ORFs 1 and 2 has been identified as the 
core promoter for NoV subgenomic RNA synthesis by binding with the viral RNA-dependent RNA 
polymerase (RdRp) (Bull et al., 2005; Lin et al., 2015; Thorne and Goodfellow, 2014; Yunus et al., 
2015).  
The NoV genome is organised into three or, for MuNoV, four ORFs (Figure 3) (McFadden et 
al., 2011). The 5’ proximal ORF1 encodes a large polyprotein that is co-and post- translationally cleaved 
by a virus-encoded protease into six non-structural proteins (NS) involved in replication complex 
formation (NS1/2, NS3, NS4), genome linkage (NS5, VPg), polyprotein processing (NS6), and genome 
replication (NS7, RdRp) (Thorne et al., 2012; Thorne and Goodfellow, 2014). Alternative names exist 
for HuNoV- and MuNoV NS proteins (Sosnovtsev et al., 2006); throughout this thesis the names related 
to MuNoV will be utilised. ORF2 and ORF3, both translated from subgenomic RNA, encode the 
structural components of the virion, the major viral protein (VP1) and minor viral protein (VP2), 
respectively. Open reading frame 4, unique to MuNoVs, overlaps ORF2 and is also translated primarily 
from subgenomic RNA; it encodes the virulence factor 1 (VF1) which is involved in regulation of innate 
immunity and apoptosis. The functions of various NoV proteins are discussed further in the context of 
the NoV replicative cycle (chapter 1.4.). 
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1.3 Virion morphology  
The NoV capsid is typically 27-30 nm in diameter and displays a T=3 icosahedral symmetry; 
cup-like depressions, characteristic for caliciviruses, are localised at the three- and fivefold symmetry 
axes (Figure 4). Each capsid is composed of 180 copies of monomeric major structural protein VP1 
which form 90 dimeric capsomers (Prasad et al., 1994, 1999). Each VP1 comprises a short N-terminal 
arm of unknown function, a shell domain (S), and a protruding domain (P) forming dimeric VP1 arches 
(Figure 4) (Prasad et al., 1999). The well-conserved N-terminal S domain faces the interior of the capsid 
and forms a continuous surface surrounding the viral RNA. The P domain, linked to the S domain 
through a flexible hinge, corresponds to the C-terminal part of VP1. It is postulated to confer increased 
stability to the icosahedral capsid and to provide a control for the size of viral particles (Bertolotti-Ciarlet 
et al., 2002). The P domain is further divided into a proximal P1 stalk subdomain at the base of the 
arches and the highly variable distal P2 subdomain. Localised at the tips of the arches, the exposed P2 
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subdomain interacts with neutralizing antibodies and contains the defined host receptor binding site for 
MuNoVs (Graziano et al., 2020) and putative receptor binding site for HuNoVs (Chakravarty et al., 
2005; Graziano et al., 2019; Hutson et al., 2004; Orchard et al., 2016).  
Minor structural protein VP2 (Glass et al., 2000), encoded by all caliciviruses, is located at the 
interior of the viral capsid and bound to a conserved motif in the VP1 S domain. It is postulated to be 
involved in MuNoV encapsidation via an interaction with viral genomic RNA (Thorne and Goodfellow, 
2014; Vongpunsawad et al., 2013) and acidic regions of VP1 (Thorne et al., 2012) and is held to regulate 
expression and stability of VP1 in HuNoVs (Bertolotti-Ciarlet et al., 2003; Liu et al., 2019). VP2 
integrity has been shown to be essential for productive replication of infectious feline calicivirus 
(Sosnovtsev et al., 2005). Feline calicivirus VP2 forms a portal-like assembly following host cell 
receptor engagement and is hypothesised to function as a channel for viral genome release from the 
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1.4 Replicative cycle  
 
1.4.1 Attachment, receptor engagement, endocytosis, and uncoating 
As the initial step of the NoV replicative cycle and decisive early determinant of cell tropism, 
host range, and pathogenesis, the multi-phasic process of viral entry commences via virion attachment 
to the cell surface (Marsh and Helenius, 2006). Attachment of NoVs is mediated by binding of the virus 
to both cell-associated and soluble host factors (Graziano et al., 2019).  
HuNoVs are bound by histo-blood group antigens (HBGAs), as evidenced by in vitro assays 
(Marionneau et al., 2002) as well as multiple volunteer studies documenting the correlation between 
long-term resistance to infection with certain HuNoV strains and FUT2 gene-mediated genetic 
polymorphisms that determine host secretor status (Johnson et al., 1990; Thorven et al., 2005). The 
ability to secrete a diverse set of fucosylated HBGAs into body fluids and on mucosal cells (secretor) is 
associated with HuNoV susceptibility; expressing only a limited array of HBGAs (non-secretor) is 
linked to resistance to certain HuNoV strains (including genogroups GI.1 and prevalent GII.4) 
(Lindesmith et al., 2003; Nordgren and Svensson, 2019). While non-secretors thus experience infections 
with a lesser variety of NoV strains, the resistance to HuNoV is not absolute and they can become 
infected by secretor-independent strains (GII.3, GII.7, and GII.6), implicating non-HGBA ligands 
(fucosylated and sialylated carbohydrates (Wegener et al., 2017)) and co-factors in HuNoV binding 
(Almand et al., 2017; Graziano et al., 2019; Lindesmith et al., 2020). 
In addition to binding to host HBGAs, NoVs may also bind directly to HBGAs expressed by 
commensal bacteria in the gut (Miura et al., 2013b), which may thus act as proviral co-factors for 
HuNoV infection; in this context, HuNoV B cell infection is enhanced by HBGA-producing bacteria or 
free synthetic HBGAs (Jones et al., 2014). While HGBA binding apparently plays no role in MuNoV 
infection, a dependency on faecal microbiota has been demonstrated for MuNoVs in vitro (Jones et al., 
2014) and in vivo (Baldridge et al., 2015); thus, bacterial depletion via antibiotic treatment of mice 
prevents infection with both acute and persistent MuNoV strains (Baldridge et al., 2015) and 
susceptibility to persistent strains has been linked to changes in target cell numbers (tuft cells are targets 
of persistent MuNoV strains; see below) which may be regulated by the presence and composition of 
gut microbiota and their metabolites (Wilen et al., 2018). 
For MuNoVs, non-essential carbohydrate attachment factors including heparan sulfate 
proteoglycans and terminal sialic acid have been shown to enhance viral VP1 binding in a strain-
dependent manner (Orchard et al., 2016; Taube et al., 2012, 2009). Notably, sialic acids have also been 
implicated in facilitating the attachment of bovine NoVs and feline calicivirus (FCV) to susceptible cells 
(Mauroy et al., 2011; Stuart and Brown, 2007). 
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Suggested host and microbial cofactors that enhance NoV attachment to cells (also in a strain-
dependent manner) include bile acids (MuNoV and HuNoV) (Ettayebi et al., 2016; Kilic et al., 2018; 
Nelson et al., 2018), phospholipids (MuNoV) (Orchard et al., 2018), and divalent cations (MuNoV) 
(Nelson et al., 2018). 
The second step of viral entry is the engagement of host receptors to actively promote viral 
access to cells. CD300lf, an immunoglobulin domain-containing integral membrane protein expressed 
in myeloid cells, lymphoid cells and intestinal epithelial tuft cells (Borrego, 2013), has been identified 
as the primary physiologic cellular MuNoV receptor (Orchard et al., 2016). It functions by binding the 
apical side of the P2 subdomain and is essential for infection of diverse MuNoV strains both in vitro 
and in vivo independent of infection route (Graziano et al., 2020);  its paralogue CD300ld has also been 
demonstrated to be sufficient for MuNoV infection in vitro. Ectopic expression of murine CD300lf on 
human and other mammalian cells has been shown to be sufficient to confer cross-species permissivity, 
effectually breaking the species barrier and allowing MuNoV replication in non-murine cells (Orchard 
et al., 2016). Human CD300lf is not a receptor for HuNoVs and the HuNoV receptor remains unknown 
(Graziano et al., 2020). 
The details of which mechanisms are involved in the endocytic internalisation of HuNoV 
particles following receptor engagement are unknown. For MuNoVs, entry into permissive macrophages 
and dendritic cells is known to be rapid, requiring host cholesterol and dynamin (Gerondopoulos et al., 
2010; Perry and Wobus, 2010). This viral endocytosis is independent of pH (Perry et al., 2009), clathrin 
and caveolae, and is neither mediated by phagocytosis nor micropinocytosis (Perry and Wobus, 2010). 
For bovine NoVs, VLP internalisation into permissive cells involves both the cholesterol-dependent 
pathway and macropinocytosis (Mauroy et al., 2011). 
After endocytosis, endosomal escape and viral uncoating are required to release the viral 
genome into the host cytoplasm. While the process remains unsolved for NoVs, a recent near-atomic 
resolution analysis of FCV  yielded important basic information regarding these important last steps of 
calicivirus entry. In the process of clathrin- and pH-dependent endocytosis, binding of FCV to its 
receptor feline junctional adhesion molecule A (fJAM-A) was shown to induce formation of a portal-
like assembly made up of twelve copies of VP2 arranged with their hydrophobic N termini pointing 
away from the virion surface around a pore in the capsid shell. The funnel-like structure is hypothesised 
to function as a channel for the delivery of the viral genome through the endosomal membrane into the 
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1.4.2 Translation and polyprotein processing 
 
Following its release into the cytoplasm of a permissive cell, the VPg-linked NoV RNA acts as 
a messenger RNA (mRNA) template for an initial round of viral RNA translation. Attached covalently 
to the 5’ end of the genome, NoV VPg (NS5) functions as a cap substitute to recruit eukaryotic initiation 
factors and mediate translation of viral RNA into protein via multiple direct interactions with the cellular 
translational apparatus of the host cell and core stress granule components (Brocard et al., 2020; 
Chaudhry et al., 2006; Daughenbaugh et al., 2006; Emmott et al., 2017; Hosmillo et al., 2019).  
Interactions between various host cell RNA-binding proteins and conserved RNA secondary structures 
of complementary sequences at the 3’ and 5’ genome extremities are further postulated to enhance and 
regulate viral protein translation, putatively by stabilising sequence-mediated, long-range physical RNA 
interactions that promote genome circularisation (López-Manríquez et al., 2013; Simmonds et al., 2008). 
Translation of the viral proteins VP1 and VP2 occurs primarily from the ORFs of the polycistronic 
subgenomic RNA which, following its transcription from genomic RNA by the NoV nonstructural 
proteins, is expressed at higher levels than the viral genomic RNA in infected cells (Asanaka et al., 
2005) in a probable strategy to augment levels of VP1 production for virus assembly (Thorne and 
Goodfellow, 2014). Translation of ORF4 in MuNoV from subgenomic RNA yields VF1 which has been 
implicated in interfering with innate immune signalling at the cellular level and was recently found to 
delay the upregulation of IFN-β and other interferon stimulated genes (ISGs) in vitro (McFadden et al., 
2011). 
 
1.4.3 Viral genome replication 
Once translated, the ORF1 polyprotein is co- and post-translationally cleaved by the viral 
protease (NS6) to release NS precursors and mature viral proteins (NS1/2 to NS7) (Emmott et al., 2019; 
Sosnovtsev et al., 2006) that then serve to assemble the replication complex by recruitment of cellular 
membranes to the perinuclear region of the cell (Hyde et al., 2009).  
MuNoV NS1/2, the least conserved NoV NS (Thorne et al., 2012), is hypothesised to be one of 
the main drivers of replication complex formation by associating with components of the endocytic and 
secretory pathway together with co-localizing NS4 (Hyde and Mackenzie, 2010; Kaiser, 2006). NS1/2 
contains an N-terminal disordered region and a C-terminal predicted trans-membrane domain (Baker et 
al., 2012). MuNoV NS1/2 has been shown to induce rearrangement of the endoplasmic reticulum. It is 
implicated in viral persistence in vivo (Nice et al., 2013) and, once unconventionally secreted via 
caspase-3 cleavage, is essential for intestinal pathogenesis of MuNoV infection and resistance to 
endogenous IFN-γ (Lee et al., 2019). Its HuNoV equivalent p48 promotes Golgi disassembly dependent 
upon the C-terminal hydrophobic region and disrupts expression and trafficking of cell surface proteins 
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by interfering with cellular vesicle transport (Doerflinger et al., 2017; Fernandez-Vega et al., 2004); a 
secreted form of HuNoV NS1 is also observed (Lee et al., 2019).  
As a constituent of the MuNoV replication complex, NS4 localises to endosomes (Hyde et al., 
2009; Hyde and Mackenzie, 2010). HuNoV NS4 (P22) has been shown to induce Golgi disassembly 
(Sharp et al., 2010) and has been identified as a key determinant in the formation of membrane 
alterations by HuNoVs (Doerflinger et al., 2017); both MuNoV and HuNoV NS4 inhibit cellular protein 
secretion (mildly in MuNoV and potently in HuNoV) (Hyde and Mackenzie, 2010; Sharp et al., 2010).  
While NS1/2 and NS4 are acknowledged to be key main mediators of replication complex 
formation, NS3, to which RNA-chaperoning and helicase activities have been attributed (Han et al., 
2018; Li et al., 2018), has also been shown to localise to cellular membranes (Hyde et al., 2009). Both 
HuNoV and MuNoV NS3 induce formation of motile membrane-derived vesicular structures that 
colocalise with the Golgi apparatus and the endoplasmic reticulum (Cotton et al., 2017; Doerflinger et 
al., 2017).  
Norovirus genome replication occurs via a negative-strand intermediate (Thorne and 
Goodfellow, 2014); subsequent to the initial round of translation of the incoming positive-stranded 
parental RNA, this mRNA serves as a template for the synthesis of negative-strand RNA from its 3’ end 
and the formation of a double-stranded replicative form. The negative-sense genomic and subgenomic 
RNAs are then used as templates for the synthesis of positive sense genomic and subgenomic RNAs 
(Thorne and Goodfellow, 2014). These transcription reactions are catalysed by the RNA-dependent 
RNA-polymerase (RdRp, NS7), using de novo mechanisms for synthesis of negative-stranded RNA 
(Subba-Reddy et al., 2017, 2012), and VPg-dependent mechanisms of positive sense genomic and 
subgenomic RNA synthesis in which the NS7 uses multifunctional VPg as a proteinaceous primer (Lee 
et al., 2018; McSweeney et al., 2019; Olspert et al., 2016). Two, not-mutually exclusive, models have 
been proposed for the generation of NoV subgenomic RNA; based on the detection of negative-sense 
subgenomic RNA copies in Norwalk virus replicon-bearing and MuNoV infected cells (Chang et al., 
2006; Yunus et al., 2015), the pre-mature termination model proposes synthesis of negative-sense 
subgenomic RNA linked to an unidentified termination signal, and subsequent generation of  positive 
sense subgenomic RNA from this template. The internal initiation model postulates that the highly 
conserved stem-loop structure upstream of the subgenomic start site in the negative-sense genomic RNA 
acts as the core of an internal subgenomic promoter and binds to the RdRp to direct initiation at the 
overlap of ORFs 1 and 2. In this case, newly synthesised subgenomic RNA may function as a template 
for further rounds of replication via a negative-sense subgenomic RNA intermediate (Bull et al., 2005; 
Lin et al., 2015; Simmonds et al., 2008; Yunus et al., 2015).  
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1.4.4 Assembly and exit 
Self-assembly of VP1 into virus-like particles (VLPs) that are morphologically and antigenically 
comparable to native virions (Bertolotti-Ciarlet et al., 2002), suggests that VP1 alone may be able to 
drive assembly of infectious NoV particles. While not essential for assembly, the 3’ UTR of the Norwalk 
mRNA can stimulate VP1 expression via putative RNA-capsid interactions and the presence of VP2 is 
held to enhance the stability of nascent particles (Bertolotti-Ciarlet et al., 2003; Lin et al., 2014; Pogan 
et al., 2018). Associated with a conserved acidic motif in the VP1 S domain at the capsid interior (Thorne 
et al., 2012; Vongpunsawad et al., 2013), the highly basic VP2 may provide the link between capsid 
subunits and acidic viral RNA (Thorne and Goodfellow, 2014; Vongpunsawad et al., 2013). 
Upon completed assembly, virion exit is the last step of the replicative cycle. Active viral 
replication of MuNoVs in permissive cells, and indeed the expression of the MuNoV polyprotein alone, 
have been shown to regulate and induce apoptosis and programmed cell death in conjunction with 
downregulation of pro-survival factor surviving in infected cells (Bok et al., 2009; Herod et al., 2014). 
While its role in viral exit remains undetermined, inhibition of apoptosis has been shown to accelerate 
cell death, change the death pathway to rapid necrosis, and to ultimately result in an over 10-fold 
reduction in infectious NoV yield (Furman et al., 2009).  
While MuNoVs lytically infect innate immune cells including macrophages and dendritic cells 
in vitro (Karst et al., 2003), the nature of in vitro B cell infection by HuNoVs and MuNoVs is distinct 
in that mature B cells are infected noncytopathically (Jones et al., 2015; Karst, 2015a), suggesting that 
different mechanisms of cellular regulation and cell exit can be employed by NoVs. The paradigm that 
nonenveloped viruses must lyse their target cells in order for progeny virions to be released 
extracellularly has further been challenged by the discovery that, amongst other enteric viruses, NoVs 
can be secreted from cultured cells inside extracellular membrane-bound vesicles and that they are shed 
in faeces within vesicles of exosomal or plasma membrane origin presenting highly virulent units of 
faecal-oral transmission (Santiana et al., 2018).  
An outline of the entire NoV replication cycle is provided in Figure 5. 
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1.5 Clinical aspects of norovirus infection 
 
1.5.1 Human noroviruses 
HuNoVs are recognised as the major global cause of sporadic and epidemic viral gastroenteritis 
(Patel et al., 2008; Robilotti et al., 2015). After a short incubation period of 24–48 hours (Lee et al., 
2013), clinical symptoms typically last for two to three days (Robilotti et al., 2015), followed by a 
median of four weeks of post-clinical shedding (Atmar et al., 2008) with peak viral titres varying 
between 105–109 genome copies/g of faeces (Teunis et al., 2015).  
Characteristic symptoms of HuNoV infection are acute onset of watery, non-bloody diarrhoea 
and projectile vomiting (Kaplan et al., 1982). Other symptoms include abdominal cramps, nausea, 
bloating, mild fever, chills, headaches and myalgia (Atmar and Estes, 2006; Gallimore et al., 2004a; 
Tseng et al., 2011). While self-limiting gastrointestinal infections are the norm, more severe intestinal 
pathologies such as necrotising enterocolitis in neonates (Stuart et al., 2010; Turcios-Ruiz et al., 2008), 
post-infectious irritable bowel syndrome (Marshall et al., 2007), and exacerbation of inflammatory 
bowel disease (Khan et al., 2009) have been described. Atypical extraintestinal pathologies such as 
seizures in young children (Chen et al., 2009; Hu et al., 2017; Ueda et al., 2015), encephalopathy (Ito et 
al., 2006), and acute liver dysfunction (Lok Tung Ho et al., 2020; Nakajima et al., 2012) have also been 
reported in association with NoV infections; NoV RNA has been detected in sera (Takanashi et al., 
2009) and cerebrospinal fluids (Ito et al., 2006) of infected individuals, suggesting possible spread to 
peripheral tissues. 
Despite typically eliciting severe gastroenteritis, HuNoVs cause only modest intestinal 
pathologies. Histopathological changes in the small intestine include broadening and shortening of the 
microvilli, crypt hypertrophy, as well as increased epithelial mitoses and apoptosis (Schreiber et al., 
1973). Decreased brush border enzyme activity, transient malabsorption of D-xylose, fat, and lactose, 
disruption of epithelial barrier functions, reduction of tight junctional sealing proteins, and stimulation 
of active anion secretion, suggest that both a leak flux and alterations of secretory and/or absorptive 
processes cause HuNoV-induced diarrhoea (Blacklow et al., 1972; Karst et al., 2015; Troeger et al., 
2009). Vomiting episodes may be linked to abnormal gastric motor functions and delays in gastric 
emptying, however the underlying pathophysiology remains unclear (Meeroff et al., 1980). 
Asymptomatic infections and viral shedding similar to that of symptomatic infections (Teunis 
et al., 2015) have been both experimentally observed in volunteer studies (Graham et al., 1994) and 
detected in various epidemiological analyses of clinically healthy individuals and those with various 
underlying illnesses resulting in impaired immunity (Ayukekbong et al., 2011; Lopman et al., 2014; 
Siebenga et al., 2008; Utsumi et al., 2017). 
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Customarily an acute and self-limiting illness, HuNoV infection can become persistent in the 
elderly (Harris et al., 2008), malnourished and/or immunocompromised (individuals with genetic or 
acquired immune-deficiencies, cancer patients undergoing treatment, transplant patients) (Brown et al., 
2017, 2016; Gallimore et al., 2004b; Vega et al., 2014; Woodward et al., 2017). These individuals often 
experience severe, even lethal, persistent or recurring NoV infections during which prolonged diarrhoea 
and vomiting can lead to weight loss and malabsorption; in these patient cohorts viral RNA remains 
detectable in stool samples for months to years (Brown et al., 2019; Gallimore et al., 2004b; Green, 
2014; Sukhrie et al., 2010).  
 
1.5.2 Animal noroviruses 
 
Animal NoVs have been linked to gastroenteritis outbreaks and acute diarrhoeic episodes of 
varying severity in cattle (Di Felice et al., 2016), pigs (Mauroy et al., 2008; Shen et al., 2012b, 2012a), 
cats (including a captive lion cub that succumbed to severe haemorrhagic enteritis) (Martella et al., 2007; 
Pinto et al., 2012), and dogs (Mesquita and Nascimento, 2012). While a clinical association typically 
exists in these domesticated mammalian hosts, asymptomatic infections have been observed (at lower 
prevalences) in epidemiological screening studies  (Cho et al., 2013; Scipioni et al., 2008a; Villabruna 
et al., 2019); the only documented GIII sheep NoVs were reportedly isolated from animals that showed 
no obvious clinical signs (Wolf et al., 2009). In wild animals such as bats (Wu et al., 2016), harbour 
porpoises (de Graaf et al., 2017a), and Californian sea lions (Teng et al., 2018), where NoVs are typically 
detected in the context of metagenomics analyses and/or retrospective analyses of stored samples, a 
potential disease association often remains undetermined. 
 
1.5.3 Murine noroviruses 
Murine noroviruses have been isolated from asymptomatic wild populations of both field and 
wood mice (Apodemus agrarius and Apodemus sylvaticus) (Farkas et al., 2012; D. B. Smith et al., 2012) 
and have been detected in various cohorts of domesticated mice (Mus musculus), including mice sold as 
pets or snake food, show animals, and those bred for academic research (D. B. Smith et al., 2012).  
Indeed, MuNoVs are recognised as one of the most prevalent, albeit often undetected, pathogens 
of contemporary laboratory mice, as evidenced by serologic testing and reverse transcription polymerase 
chain reaction (RT PCR) screening  (Hsu et al., 2006, 2005; Müller et al., 2007). Thirty fully sequenced 
MuNoV strains have been isolated from specific-pathogen-free mice in academic research colonies 
across the globe; while these strains comprise a single genetic cluster, they broadly segregate into two 
categories regarding their pathogenesis and disease profile (Kahan et al., 2011). The prototype acute 
strain MNV-1, which infects immune cells in the gut-associated lymphoid tissue, reaches peak intestinal 
titres 1-2 days post-infection (dpi) and is cleared by 7-14 dpi; persistent strains MNV-3 and MNV-CR6 
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can establish life-long infections, linked to replication in the caecum, colon, mesenteric lymph nodes, 
and rare intestinal epithelial tuft cells (Arias et al., 2012a; Hsu et al., 2006; Wilen et al., 2018). Persistent 
asymptomatic infection with typically nonpersistent strain MNV-1 CW3 has been associated with 
adaptive changes to viral proteins NS1/2, NS7 and VP2 (Borin et al., 2014; Nice et al., 2013).  
Notwithstanding differences in clearance kinetics and cell tropism, all MuNoV strains elicit sub-
clinical infections of the intestine, lacking any association with diarrhoea or other overt disease in 
juvenile and adult mice of wild-type- and certain knock-out strains. A MNV-1-induced decrease in 
faecal consistency as measured by visual scoring of faecal samples of immunocompetent mice remains 
the only modest disease-association (MNV-3 failed to induce this pathology) (Kahan et al., 2011). 
Despite a subclinical presentation, quantifiable intestinal pathology and detection of viral RNA in the 
liver, spleen, mesenteric lymph nodes, and proximal intestine (but not in the lung, brain, blood, or faeces) 
have been described in association with experimental MuNoV infection of wild-type hosts (Hsu et al., 
2005; Karst et al., 2003; Shortland et al., 2014; Wobus et al., 2006).  
In severely immunodeficient adult mice lacking functional components of the innate immune 
system and interferon (IFN) pathways, MuNoV infection has been shown to be associated with lethal 
disease (Karst et al., 2003; Wobus et al., 2006). Following oral MNV-1 inoculation, mice deficient in 
signal transducer and activator of transcription 1 (STAT1) and recombination-activating gene 2 (RAG2) 
rapidly succumb to systemic disease associated with severe weight loss, diarrhoea, bloating, pathologies 
in intestinal and peripheral tissues, and the presence of viral RNA in all organs. Persistent strains MNV-
3 and MNV-CR6 cause less overt symptoms than MNV-1 in IFN-deficient mice (Strong et al., 2012).  
Recently, self-resolving diarrhoea in the absence of systemic disease was reported in MuNoV-
infected wild-type neonatal mice, mirroring key clinical features of HuNoV disease; diarrhoeic episodes 
were neither associated with disruption of the intestinal epithelium nor notable inflammation. Oral 
MNV-1 inoculation, and to a lesser extent that of MNV-3 and MNV-CR6, caused acute diarrhoea in 
three-day-old BALB/c mice (Roth et al., 2020).  
 
1.6 Human norovirus epidemiology and transmission 
 
1.6.1 The societal burden of norovirus infections and the role of genotype GII.4  
HuNoVs are recognised as major aetiologic agents of global sporadic and epidemic non-
bacterial gastroenteritis (Patel et al., 2008; Robilotti et al., 2015), causing significant morbidity and 
mortality in developing countries and engendering enormous economic losses in developed countries 
(Bartsch et al., 2016). Causing a median number of 669 million illnesses and an estimated 219.000 
deaths across all ages per year globally, HuNoVs have been calculated to result in a yearly total of USD 
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4.2 billion in direct health care costs (outpatient visits and hospitalisation) and USD 60.3 billion in 
societal costs (productivity losses due to absenteeism or mortality) (Bartsch et al., 2016). 
GII.4 infections,  which are responsible for the majority of past HuNoV outbreaks (55-85%) and 
also sporadic cases, have been associated with a higher probability of severe outcomes and lead to higher 
hospitalisation and mortality rates (Desai et al., 2012). 
GII.4 NoVs have been the predominant genotype circulating in humans for over two decades, 
with novel circulating GII.4 strains emerging every two to three years and replacing their predecessors 
in an immune-driven selection process known as epochal evolution (Ji et al., 2013; Siebenga et al., 2007; 
Wang et al., 2012). Postulated mediators for the GII.4 dominance include selective advantages and 
improved adaptation to host receptors via physicochemical P2 changes in the virion of new GII.4 
subtypes and the evasion of herd immunity against predominant genotypes (Giammanco et al., 2012; 
Hoffmann et al., 2013; Lam et al., 2012; Motomura et al., 2010). The elevated number of novel 
nonsynonymous mutations in GII.4 capsid sequences and changing HBGA binding patterns (Boon et 
al., 2011), as well as intragenotypic recombination have long been postulated to be a driving force of 
GII.4 NoVs. Strain-dependent differences in NoV molecular evolution via the accumulation point 
mutations are briefly discussed in chapter 2.2; complex patterns of intragenotypic recombination within 
the GII.4 lineage are discussed in chapter 2.3 (Ludwig-Begall et al., 2018). 
The position of the rapidly evolving dominant GII.4 variants has only recently been challenged 
by emergence and re-emergence of different intra- and intergenotype recombinants modifying long-term 
global NoV genetic diversity trends (Bruggink et al., 2016, 2014; De Graaf et al., 2015; Fu et al., 2017; 
Hoffmann et al., 2013; Mahar et al., 2013; van Beek et al., 2018). 
 
1.6.2 Norovirus shedding and human infectious dose 
 
Norovirus particles are shed for weeks to months via the faeces or vomit of both infected 
symptomatic and asymptomatic patients (Davis et al., 2020; Leon et al., 2008; Siebenga et al., 2008).  
While the main NoV transmission route is faecal-oral transmission, with faecal loads reaching up to 109 
genomic copies/g faeces (Atmar et al., 2008; Teunis et al., 2015), transmission via vomiting has also 
been identified as a risk (de Graaf et al., 2017b). Unlike shedding through stool, vomiting is more likely 
to result in significant environmental contamination, leading to transmission through fomites and 
airborne vomitus droplets (1.7x108 genome equivalent copies are typically shed in emesis (circa 4x104 
genomic equivalent copies/ml vomitus) (Atmar et al., 2014; Kirby et al., 2016; Tung-Thompson et al., 
2015). The high doses of virus shedding stand in clear contrast to the low 50% human infectious dose 
which has been calculated to lie between 1320 and 2800 genome equivalents (Atmar et al., 2014). 
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1.6.3 Transmission routes 
Highly tenacious and resistant in the face of various decontamination methods (Ludwig-Begall 
et al., 2021; Zonta et al., 2015), HuNoVs are transmitted either via direct person-to-person contact or by 
consumption of contaminated water or food (Verhoef et al., 2015) (Figure 6). Infectious viruses can 
enter environmental waters either via direct discharge or release of improperly-treated sewage from 
industrial-scale or small private waste-water treatment plants, discharges from vessels, as well as urban 
runoff, the latter especially in times of flooding or heavy rainfall which have been linked to a high 
prevalence of HuNoVs in coastal waters (Campos et al., 2013; Campos and Lees, 2014; Hassard et al., 
2017; Wyn-Jones et al., 2011). Suspended or precipitated NoVs  have been shown to retain infectivity 
for weeks to months (Bosch et al., 2006; Campos and Lees, 2014; McIntyre et al., 2012; Seitz et al., 
2011) and have been detected up to 10 km distant from their discharge point (Campos et al., 2017; Wyn-
Jones et al., 2011).  
The foodborne proportion of HuNoV outbreaks is estimated at 14% (Verhoef et al., 2015). 
Foods implicated in outbreaks are contaminated either directly with faecal matter at the source or by 
infectious food-handlers (Hardstaff et al., 2018). The most common food vehicles remain fresh or frozen 
soft fruits and vegetables, ready-to-eat foods (such as sandwiches and salads) which require handling 
but no or little subsequent cooking, and undercooked or raw seafood (bivalve molluscs) (Razafimahefa 
et al., 2019). Bivalve molluscs, including cockles, mussels, clams, scallops, and oysters, accumulate 
NoVs via filter feeding; large volumes of water are pumped through the ctenidia, the molluscs’ 
respiratory and feeding organs, in a process which filters not only nutrients but also contaminating 
bacteria and viruses. Depuration practices, which aim at eliminating such bioaccumulated pathogen 
charges are unsuccessful in the face of NoV contamination. Increasingly, this effect is attributed to the 
fact that NoVs are not only filtered and concentrated through nonspecific interactions, but are also bound 
in a genogroup- and strain-dependent manner to molluscan gastrointestinal carbohydrate structures 
(HBGA-like moieties and sialic acid-residues) (Almand et al., 2017). As known “hotspots” for the 
accumulation of  multiple NoV strains (de Graaf et al., 2016; Lysén et al., 2009), bivalve molluscs have 
been postulated to present opportunities for infectious HuNoV inter-and intragenotype co-infection (thus 
facilitating subsequent viral recombination within the host), and have been pinpointed as high-risk 
vectors for the introduction of novel recombinant strains into the human population (Ludwig-Begall et 
al., 2018; Rajko-Nenow et al., 2013). In a similar context, bivalve molluscs, as potential interfaces of 
shared species exposure through filtration of human and animal waste, have also tentatively been 
implicated as a putative way of introducing both human and different animal NoVs into a single host 
(Ludwig-Begall et al., 2018; Takano et al., 2015). 
Norovirus outbreaks are often reported in the context of communal dining at restaurants, 
festivals, picnics, schools, cruise ships and military bases (Pringle et al., 2015; Rha et al., 2016; A. J. 
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Smith et al., 2012; Verhoef et al., 2008) or in institutional settings such as hospitals and care homes, 
where spread of infection from a common-source exposure is facilitated by enclosed living quarters and 
reduced personal hygiene (Mathijs et al., 2012; Patel et al., 2009; Sukhrie et al., 2012, 2010). 
Recently, wild  birds and rodents were named as new potential HuNoV transmission routes; GI 
and GII HuNoV genome copies were detected in faecal samples of gulls and crows (31%) and rats (2%), 
implicating them as mechanical carriers, capable of spreading HuNoVs in the environment and possibly 
transmitting the virus to humans directly or indirectly by contaminating foods (Summa et al., 2018). 
Determination of the replication capability of HuNoVs in these new potential carriers (e.g. by detection 
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1.6.4 Immunity to noroviruses 
Many gaps remain in the understanding of natural immunity to HuNoVs. In addition to genetic 
resistance to infection based on secretor status (see chapter 1.4.1), with non-secretors representing as 
much as 20% of the European population (Le Pendu et al., 2006), NoV infection has been shown to 
result in development of clinical immunity.  
Upon RNA virus invasion, two main innate immune cell pathways are rapidly launched against 
intestinal RNA viruses such as NoVs. Recognition of conserved viral pathogen–associated molecular 
patterns by germline-encoded pathogen recognition receptors upregulates transcription of genes 
involved in antiviral responses and activates both type I and type III IFN systems to control viral 
replication, clear pathogen-infected cells, and coordinate adaptive immune responses (Campillay-Véliz 
et al., 2020; Jensen and Thomsen, 2012; Lee and Baldridge, 2017). Both toll-like and retinoic acid-
inducible gene I-like receptor family members sense cytosolic viral RNA  and signal via mitochondrial 
antiviral-signalling protein to stimulate transcription of type I and III IFNs by members of the IFN 
regulatory factor family. Both type I IFNs (13 subtypes of IFN-α, IFN-β, κ, ω, ε, δ, and τ), which signal 
through the ubiquitous IFNα/β receptor to regulate IFN-stimulated gene expression through 
phosphorylation of STAT proteins (Cho and Kelsall, 2013), and type III IFNs (IFN λ or interleukin-
28/9), which  are produced by leukocytes and epithelial cells and signal through the IFNλ receptor 
expressed on epithelial cells, but also type II IFNs (IFN γ), have been shown to be critical for control of 
HuNoV and MuNoV replication. Thus, findings show that natural HuNoV infection results in the 
production of proinflammatory and anti-inflammatory cytokines (Cutler et al., 2017), that HuNoV 
replication in zebrafish larvae results in a measurable innate response (Van Dycke et al., 2019), and that 
the innate immune response partially restricts HuNoV replication in human intestinal epithelial cells 
(IECs) through IFN-induced transcriptional responses and production of pro- and anti-inflammatory 
cytokines (Hosmillo et al., 2020). Mice lacking functional type I and II IFN pathways succumb to lethal 
MuNoV infections (Karst et al., 2003). Type I and II IFNs play a role in the control of acute MuNoV 
infections both in vivo and in vitro (Changotra et al., 2009) but are dispensable for intestinal regulation 
of persistent strains for which IFN-λ instead plays a critical regulatory role (Lee and Baldridge, 2017; 
Nice et al., 2015). 
Adaptive immunity against HuNoVs is postulated to include both cellular and humoral 
responses (Campillay-Véliz et al., 2020; van Loben Sels and Green, 2019). While information on 
cellular responses to HuNoV infection is scarce, increases of various pro- and anti-inflammatory 
cytokines in volunteer serum samples indicate involvement of both Th1 and Th2 immune responses 
(Lindesmith et al., 2005). Humoral immunity to HuNoVs is considered to be stronger and more long-
lasting than cellular immunity; based on human challenge studies, first estimates of immunity duration 
suggested short term, adaptive immunity to homotypic Norwalk re-challenge with high viral doses to 
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last from two months to two years (Parrino et al., 1977) or for longer than six months (Johnson et al., 
1990). Epidemiological data and mathematical modelling have since suggested that naturally induced 
immunity in the absence of major strain changes may actually last for much longer and potentially span 
up to a decade (Simmons et al., 2013). While seroprevalence studies have shown an estimated 90% of 
adult populations to be seropositive to NoV (O’Ryan et al., 1998), probably only a small fraction of the 
total HuNoV specific antibodies represent partial or even absolute neutralising antibodies, i.e. correlates 
of protection that mediate reduced infection or disease severity (van Loben Sels and Green, 2019). Strain 
dependent differences in the induction of protective immune responses (Zhu et al., 2013), antigenic 
diversity and known lack of heterotypic cross-protection between certain NoV genogroups, genotypes 
and strains (Rockx et al., 2005a) further confound the determination of immunity duration (Cates et al., 
2020). 
A recent model of adaptive immune responses to MuNoV infection suggests that presentation 
of MuNoV peptides on major histocompatibility complex class I molecules leads to the stimulation of 
primary Th1 proinflammatory responses, whereupon CD4+ Th1 cells release various cytokines that 
upregulate the activity of CD8+ cytotoxic T lymphocytes (van Loben Sels and Green, 2019). Humoral 
immunity supplements the Th1 response and has been shown to play a critical role in MuNoV clearance 
(Chachu et al., 2008) and protection from subsequent challenge (in this context it is noteworthy that 
MuNoVs are less diverse genetically and constitute a single genotype) (Zhu et al., 2013); proposed 
responses involve migration of antigen presenting cells to mesenteric lymph nodes where they present 
MuNoV antigens on major histocompatibility complex class II molecules and elicit upregulation of Th2 
responses to help mature B cells (van Loben Sels and Green, 2019). 
 
1.6.5 Seasonality of human norovirus infections 
 
True to the name “winter vomiting disease”, HuNoV infections follow a typical seasonality with 
incidents peaking during the winter months from October to March (Lopman et al., 2009). While not 
fully elucidated, this pattern is attributed to a complex combination of host, climactic environmental and 
viral factors. On the host side, winter peaks in NoV infections are linked to changes in societal 
behaviour, an upsurge in hospitalisations due to other infectious diseases, and fading herd immunity; 
inverse linear associations of NoV laboratory reports and daily temperatures have been reported, linking 
cold, dry conditions to higher NoV activity. NoV levels typically peak in winter in sewage (Nordgren 
et al., 2009; Victoria et al., 2010), freshwater (Westrell et al., 2006; Pérez-Sautu et al., 2012) and 
seawater as conditions for NoV persistence in waters are improved by colder water temperatures and 
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1.6.6 Reservoirs 
The excretion of infectious NoV from persistently infected individuals (Davis et al., 2020; 
Teunis et al., 2015) is purported to be one of the sources of NoV outbreaks. Not only has the involvement 
of chronic shedders in hospital outbreaks indicated them to be a reservoir for nosocomial transmission 
of NoVs (Sukhrie et al., 2010), but persistently infected patients have also been suggested to contribute 
to HuNoV transmission as reservoirs for emerging strains.  
Intra-host evolution via point mutation accumulation (Hoffmann et al., 2012; Yu et al., 2020) 
and the acquisition of superinfections over the protracted period of persistent infections (Brown et al., 
2017) implicate persistently infected patient cohorts as potential reservoirs for novel HuNoV variants 
(de Graaf et al., 2016). Multiple phylogenetic analyses have identified viral populations in persistently 
infected patients to be highly diverse and genetically distinct from viruses circulating in the general 
population (Bull et al., 2012; Green, 2014).  
The within-host viral variation via the acquisition of point mutations in chronic shedders is 
typically not random but has been shown to be a result of positive selection, as evidenced both by 
nonsynonymous versus synonymous substitution ratios (>1) and the clustering of amino acid changes 
at VP1 blocking epitopes (hypervariable P2 domain) and HBGA binding sites on the capsid surface 
(Hoffmann et al., 2012; Nilsson et al., 2003; Siebenga et al., 2008; Van Beek et al., 2017; Yu et al., 
2020). Indeed, the intra-host emergence of antigenically distinct strains comparable to the variation 
between chronologically predominant GII.4 strains has been observed, suggesting that in certain 
individuals the evolution during a persistent NoV infection translates into relevant phenotypic 
variability, thus potentially selecting for viruses able to escape herd immunity to earlier isolates  
(Debbink et al., 2014).  
At an average of five to nine mutations per 100 days (Hoffmann et al., 2012) or 1.85 to 2.66 x 
10-2 substitutions per nucleotide site per year (s/n/y) in the viral capsid gene (Nilsson et al., 2003), NoV 
evolution rates in immunocompromised hosts are generally significantly elevated compared to those in 
healthy hosts. The process, whereby NoV strains can acquire enough mutations to constitute novel 
epidemic subtypes within weeks to months (on a global scale this would normally take years), has been 
attributed to the particularities of a reduced but constant intra-individual selection pressure in 
immunocompromised hosts (Hoffmann et al., 2012; Karst and Baric, 2015; Siebenga et al., 2008). 
Siebenga et al. reported that the number of VP1 amino acid changes selected per time in intra-individual 
quasispecies was higher in patients with intermediate immunocompromise than in severely 
immunocompromised patients (Siebenga et al., 2008). This is concurrent with the phylodynamic 
framework for RNA virus evolution proposed by Grenfell et al., which argues that highest rates of 
pathogen adaptation occur at intermediate levels of immunity when medium immune pressure coincides 
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with appreciable virus replication and the co-evolutionary competition between host and pathogen is 
most intense (Grenfell et al., 2004).  
Over the prolonged period of persistent NoV infections, superinfections with a second genotype 
have been shown to occur in a sixth of patients; in such cases, temporary mixed infections can be 
detected in a single sample (Brown et al., 2017). Mixtures of NoV strains further heighten the 
complexity of intra-individual quasispecies in immunocompromised hosts and provide opportunities for 
viral recombination, which constitutes another possible factor towards driving the emergence of new 
epidemic strains (Ludwig-Begall et al., 2018; Parra, 2019). 
While multiple analyses have highlighted the diversity of NoV variants in immunocompromised 
patients and have shown that chronic variants have the propensity to rapidly generate novel variants, the 
contribution of this diversity to NoV evolution at the inter-host population level is still unclear. Recent 
mathematical modelling based on the standard epidemiological categorisation of susceptible, infected 
and recovered individuals, suggested that despite the capacity of immunocompromised hosts to generate 
significant diversity, the relative isolation and rarity of such hosts limits their impact on broader 
pathogen evolution and epidemiology. Specifically, only a minor role for immunocompromised 
individuals in shaping large scale evolutionary patterns and processes and the global emergence of new 
HuNoVs was inferred (Eden et al., 2017). However, the model presented several inherent caveats, 
notably the implicit assumption within the modelling framework for there to be no selective advantage 
of novel genetic variants (all nucleotide substitutions were considered to be effectively neutral), the fact 
that varying immune pressures were not accounted for, the disregard of superinfections and the potential 
for mixed viral recombination in immunocompromised patients, and the failure to account for complex 
host population structures in institutional settings. 
While the reservoir of novel NoV strains is yet to be definitively identified, NoV diversity could 
also be originated at inter- and intra-host levels in otherwise healthy populations of different age groups 
(from infants in day care centres (Hebbelstrup Jensen et al., 2019) to adults in the context of communal 
living and dining as described above). Thus, mutations could arise during transmission events which 
present an evolutionary bottleneck in outbreak settings,  and/or during shedding in healthy individuals 
(Bull et al., 2012; Parra, 2019).  
The lack of certitude regarding the source of newly emerging HuNoVs and  the close genetic 
relatedness between certain animal and human NoVs have generated interest in the possible role of 
animals as a potential zoonotic reservoir for emerging strains (Villabruna et al., 2019). More than two 
thirds of human emerging infectious diseases  are thought to originate from animal reservoirs (Jones et 
al., 2008); for other members of the Caliciviridae family, interspecies transmission has been reported 
(Smith et al., 1998, 1973). The as yet unproven existence of a zoonotic potential for NoVs has long been 
discussed, potential interfaces of shared species exposure being food, water or animal contact. Despite 
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known NoVs exhibiting marked host specificity, the discussion about interspecies and/or zoonotic 
transmission is fuelled by the close relationship of certain animal and human NoV strains, detection of 
HuNoVs in animal faeces, detection of antibodies against HuNoVs in swine, and the demonstration of 
experimental HuNoV GII infection in gnotobiotic pigs (Bank-Wolf et al., 2010; Mathijs et al., 2012; 
Scipioni et al., 2008a; Wilhelm et al., 2015). Questions concerning species barrier determinants 
preventing HuNoV infection of murine cells were recently resolved with the identification of a CD300If 
proteinaceous receptor as the primary determinant of MuNoV species tropism. All other components of 
cellular machinery required for NoV replication are conserved between humans and mice (Orchard et 
al., 2016); expression of MuNoV CD300 family receptor molecules rendered non-murine mammalian 
cells susceptible to MuNoV infection (Haga et al., 2016). If the key to cross-species transmission lies 
only at a structural virus-host receptor level, this presents ORF1/2 NoV recombination (discussed further 
in chapter 2.3.1), by which a nascent recombinant virus gains a complete novel capsid protein set, in an 
interesting light, in that a “lucky” intragenogroup recombination event between two co-infecting viruses 
might tender a zoonotic/ interspecies recombinant. Indeed, putative GIV.2_GVI.I interspecies 
recombinant FNoVM49, isolated from a cat captured near a Japanese oyster farm in 2015 (Takano et 
al., 2015), may have originated via a similar mechanism. However, since conclusive data supporting 
inter-species transmission is yet lacking, the continuous emergence of new HuNoV through zoonotic 
events is unlikely. 
 
1.7 Detection and typing of noroviruses  
 
1.7.1 Diagnostic methods 
Since NoV infections present a major public health issue, rapid diagnosis is vital for the 
initiation of appropriate control measures to curtail viral spread and curb the extent of outbreaks. 
Based on the typical clinical presentation of NoV infections, the Kaplan criteria can assist in 
diagnosis when laboratory resources are unavailable to determine an outbreak aetiology. Developed 
from pooled data of gastroenteritis outbreaks between 1967 and 1980, the Kaplan criteria consist of four 
patterns that characterise NoV outbreaks; accordingly, stool cultures negative for bacterial pathogens, 
mean (or median) duration of illness of 12–60 hours, vomiting in greater than or equal to 50% of cases, 
and a mean (or median) incubation period of 24–48 hours satisfy the criteria for a Norwalk-like infection 
(Kaplan et al., 1982). While a useful diagnostic aid in discriminating confirmed foodborne 
gastroenteritis outbreaks due to NoVs from those due to bacteria with a reportedly high specificity 
(99%), these criteria are only moderately sensitive (68%) (Turcios et al., 2006), necessitating further 
laboratory confirmation of the viral aetiology.  
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Electron microscopy, utilised for the first ever identification of NoV particles in stool (Kapikian 
et al., 1972), permits rapid and direct visualisation of NoVs and other gastroenteritis viruses such as 
rotaviruses, adenoviruses, astroviruses, and sapoviruses. However, the method lacks sensitivity and 
facile implementation (highly trained personnel is a prerequisite to its use), rendering it ineligible for 
routine diagnostics (Vinjé, 2015). In lieu of this costly method, and in the absence of a stable and 
inexpensive HuNoV cell culture system, routine laboratory diagnostics for NoVs are typically either 
performed via immunological assays or amplification of viral nucleic acids.  
While the development of a broadly reactive NoV antigen enzyme immunoassay (EIA) has 
proven challenging owing to the number of antigenically distinct HuNoV genotypes and the continuous 
antigenic drift of certain strains (Chan et al., 2016), several EIAs are commercially available for the 
detection of NoV GI and GII antigens in stool specimens. Most commercial kits consist of solid-phase, 
sandwich-type immunoassays and include combinations of multiple cross-reactive monoclonal and 
polyclonal antibodies. Sensitivity and specificity of these kits, typically around 70% and 90%, 
respectively, are subject to significant variation depending on the viral load and NoV genotypes present 
in the sample. The clinical context of sample collection (sporadic case versus outbreak) and the number 
of samples tested are recognised to influence the sensitivity of EIAs to such an extent that their use, 
while undoubted for rapid screening of multiple faecal samples during an outbreak of acute 
gastroenteritis, is not recommended in interpreting test results from sporadic cases and that negative 
results should be further confirmed by molecular methods (RT-PCR) (Costantini et al., 2010; Gray et 
al., 2007). Similarly, immunochromatographic lateral flow assays, designed for rapid and uncomplicated 
testing of individual faecal samples, have been shown to have a varying, genogroup-dependent 
sensitivity and, while useful for preliminary screening in outbreaks, their negative results should be 
verified by RT-PCR (Ambert-Balay and Pothier, 2013).  
Amplification-based techniques for the detection of NoVs in clinical samples, environmental 
samples, and food and water include conventional RT PCR (Vinjé et al., 2003) and one- or two-step 
quantitative real-time RT PCRs (RT qPCR) (Kageyama et al., 2003). Most contemporary assays use 
genogroup-specific oligonucleotide primers and fluorescent probes typically targeting a small conserved 
genome region at the ORF1/ORF2 junction (Katayama et al., 2002). Increasingly, such assays are 
multiplexed, allowing simultaneous detection of multiple NoV genotypes within different genogroups, 
e.g. the simultaneous detection of GI and GII strains (Rolfe et al., 2007; Shigemoto et al., 2011) or GI, 
GII, and GIV strains (Miura et al., 2013a); several different multiplex molecular gastrointestinal 
diagnostic pathogen platforms are commercially available (Claas et al., 2013). 
Quantitative RT qPCR assays, which implement either intercalating dyes (Scipioni et al., 2008b) 
or fluorescent probe-based chemistries (Miura et al., 2013a), can be used to determine the amount of 
nucleic acid (genomic copies) in a sample. However, a distinction between infectious and non-infectious 
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virus particles is not possible and virus detection by RT qPCR does not necessarily correlate with a true 
infectious NoV burden. Methods to evaluate the correlation between genomic copies and infective NoV 
particles are under investigation. Amongst these, the binding long-range PCR (Li et al., 2014) has been 
proposed to assess genome integrity and the use of a ligand binding step prior to RT qPCR (Afolayan et 
al., 2016; Dancho et al., 2012) or viability PCR assays (Karim et al., 2015; Razafimahefa et al., 2021) 
are utilised to investigate capsid integrity. Comparison of RT qPCR results with newly developed 
HuNoV infectivity assays (further discussed in chapter 1.9) may help determine cycle threshold cut offs 
for clinical diagnostic RT qPCRs, allowing estimation of infectious virus burdens to help guide infection 
control (Chan et al., 2019; Straub et al., 2013). 
Increasingly, the spectrum of analytical techniques is being widened; promising developments 
in the field include biosensors (such as monoclonal antibodies, aptamers, porcine gastric mucin, and 
HBGAs), investigated for their potential of concentrating NoVs, microarray-based assays (Yu et al., 




With the increasing implementation of molecular methods in NoV diagnostics, virus typing 
through (partial) sequence analysis has become increasingly common. The web-based, open access 
Norovirus Automated Genotyping Tool (Version 2.0; NoroNet) for sequence-based typing, available 
online from the NoroNet website of the Dutch National Institute for Public Health and the Environment 
(http://www.rivm.nl/mpf/norovirus/typingtool), provides direct and internationally standardised 
genotyping of NoVs. Based on genetic homology and phylogenetic inferences, the tool assigns 
sequences to a NoV genogroup, maps query sequences to a specific location on the reference genome(s), 
and offers information on RdRp- and capsid affiliation on either side of the ORF1/2 overlap. Briefly, 
the tool, updated periodically with new names and reference strains, employs a typing algorithm on 
ORF1 and ORF2 sequences of GI and II NoVs, starting with BLAST analysis of the query sequence 
against a reference set of Caliciviridae sequences. This is followed by phylogenetic analysis of the query 
sequence and a sub-set of the reference sequences to assign NoV genotype and/or variant (GII.4), with 
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1.8 Treatment and prophylaxis 
 
Despite the clinical significance and societal burden of NoV infections, neither approved 
antivirals nor licensed vaccines are yet available to combat this pathogen.  
 
1.8.1 Antivirals 
While medical intervention is rarely needed in typical NoV infections of immunocompetent 
individuals, safe and effective antivirals are essential for treatment of high-risk, persistently infected 
immunocompromised individuals and other vulnerable populations (juvenile/elderly). In the absence of 
specific therapeutic measures, treatment is focused on providing supportive care such as rehydration. 
Research efforts towards antiviral development have been furthered by a deeper understanding 
of the NoV replicative cycle and recent breakthroughs in culturing HuNoVs; direct acting antiviral 
therapies target various stages of the NoV replication cycle (Arias et al., 2013; Netzler et al., 2019). 
Strategies to prevent NoV attachment and entry include HBGA binding inhibition via various 
glycomimetic compounds (Koromyslova et al., 2017, 2015; Zhang et al., 2013) and passive 
immunotherapy with monoclonal antibodies (Chen et al., 2013) or nanobodies (Koromyslova and 
Hansman, 2017).  
The activity of NS6 protease inhibitors depends on preventing polyprotein processing by the 
viral NS6. Candidate drugs targeting this step include broad-spectrum antivirals that covalently bind to 
the catalytic site of  3C or 3C-like proteases (Kim et al., 2012), enzymatic transition state inhibitors or -
analogues (Galasiti Kankanamalage et al., 2016).  
Compounds targeting viral polymerase NS7 to interfere with NoV replication comprise chain-
terminating and mutagenic nucleoside analogues as well as non‐nucleoside inhibitors. Nucleoside 
analogues under investigation include the cytidine analogue 2′‐C‐methylcytidine (Rocha-Pereira et al., 
2015b) and its derivatives, and purine analogues favipiravir (Arias et al., 2014) and ribavirin, the latter 
of which is licensed to treat chronic hepatitis C infections (Chang and George, 2007; Perales et al., 2013; 
Woodward et al., 2017). Their inhibitory effects are attributed to multiple modes of action including 
chain termination, provocation of an error catastrophe scenario for the viral quasispecies via ambiguous 
base pairing (lethal mutagenesis), direct RdRp inhibition, and unbalancing of intracellular NTP pools 
(Crotty et al., 2002; Graci and Cameron, 2006). Non-nucleoside inhibitors target binding pockets of the 
RdRp thus preventing conformational changes required for formation of an active replication complex 
(Mastrangelo et al., 2012). 
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Host factor drugs with the potential to treat NoV infections include immunomodulators (type I, 
II and III IFNs) (Changotra et al., 2009; Nice et al., 2015; Rocha-Pereira et al., 2015a) and small 




The development of HuNoV vaccines is desired to protect vulnerable populations 
(immunocompromised/juvenile/elderly) and high-risk groups, including health care workers, military 
personnel, and (cruise ship) travellers experiencing crowding conditions. Prophylactic applications may 
also include the vaccination of food handlers to reduce the occurrence of food-borne outbreaks.  
Key challenges for NoV vaccine development pertain to vaccine effectiveness in the face of 
NoV strain diversity and continuing evolution, which call for multivalent vaccines and periodic updates 
to protect against a range of current and emerging epidemiologically important genotypes. Further, the 
lack of a universally accepted correlate of protection against NoV, documented varying seroresponse 
and uncertainty regarding the duration of long-term immunity conferred by NoV infection (see chapter 
1.6.4) or vaccination are barriers faced in NoV vaccine development (Hallowell et al., 2019). 
Nevertheless, a bivalent GI.1/GII.4 VLP vaccine (Treanor et al., 2020) and a recombinant 
adenovirus vector vaccine expressing GI.1 or GII.4 VP1 with monovalent or bivalent dosing (Kim et 
al., 2018), are currently in clinical trials. Further vaccines have been approved for clinical trial testing 
or are in the pre-clinical phase of development (Cates et al., 2020; Lucero et al., 2018). 
 
1.9 Model systems to study norovirus biology 
 
1.9.1 In vivo model systems for human noroviruses 
Early volunteer challenge studies and epidemiological observations of HuNoVs in their natural 
hosts have yielded important in vivo data to further the understanding of HuNoV infections (Johnson et 
al., 1990; Le Pendu et al., 2006; Meeroff et al., 1980). However, since the interpretation of results from 
such studies may not only be complicated by small sample sizes, variations in susceptibility to infection, 
previous history of exposure and cross-reactivity of antibodies, but may also pose potential health risks 
to participants, a robust HuNoV animal model has long been sought. 
Various non-human primates have been tested as HuNoV infection models (Todd and Tripp, 
2019). While neither baboons, common marmosets, cotton top tamarins nor cynomolgus seem 
susceptible to HuNoV infection (Rockx et al., 2005b), rhesus macaques and chimpanzees produce serum 
antibodies and shed virus upon oral HuNoV infection but do not develop clinical symptoms (Bok et al., 
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2011; Rockx et al., 2005b; Wyatt et al., 1978); only infection of pigtail macaques has been shown to 
result in typical clinical illness including vomiting, thus potentially presenting a model to study the 
emetic response to HuNoVs (Subekti et al., 2002).  
Large animal models for symptomatic HuNoV infection include gnotobiotic pigs and calves. 
Infection of gnotobiotic piglets with a GII.4 HuNoV results in mild diarrhoea, faecal shedding of viral 
RNA, expression of viral RNA in intestinal enterocytes and extra-intestinal lymphoid tissues, and 
seroconversion (Cheetham et al., 2006; Park et al., 2018). Prolonged HuNoV infections and viral 
dissemination beyond the intestine have been observed in gnotobiotic pigs with a severe combined 
immunodeficiency phenotype (Lei et al., 2016). Gnotobiotic piglets provide a useful experimental model 
as the pig intestine anatomy resembles that of humans and protection from disease provides a valuable 
read-out in vaccine trials and testing of therapeutics (Bui et al., 2013; Kocher et al., 2014). Gnotobiotic 
calves infected orally with HuNoV develop diarrhoea associated with intestinal damage and faecal viral 
shedding for up to six days, as well as local and systemic immune responses (Souza et al., 2008) .  
Double knockout recombination activation gene (Rag-/-) and common gamma chain (γc-/-) 
deficient BALB/c mice support subclinical HuNoV GII.4 replication upon infection via the 
intraperitoneal route (Taube et al., 2013). The model has been used to assess the anti-HuNoV activities 
of antiviral compounds (Kolawole et al., 2016). However, since these mice cannot be infected orally 
and lack both gut-associated lymphoid tissues and the ability to produce numerous cytokines and mature 
B and T cells, the model cannot recapitulate typical HuNoV infection.  
Recently, multiple HuNoV GI and GII strains were shown to replicate to high titres in cells of 
both the hematopoietic lineage and the intestine of zebrafish larvae (Danio rerio) following yolk 
inoculation (larval food reserve) (Van Dycke et al., 2019). Yielding over three orders of magnitude 
(3log10) increases in GII.4 viral RNA copies, zebrafish larvae were shown to constitute a simple and 
robust in vivo HuNoV replication model and were also demonstrated to be suited to antiviral studies.  
 
1.9.2 Human norovirus tropism and in vitro culture of human noroviruses 
In lieu of a stable HuNoV culture system, HuNoV in vitro assays were, until very recently, 
conducted using the Norwalk virus replicon (Chang et al., 2006) and/or virus-like particles (VLPs).  
The Norwalk virus RNA replicon consists of an intact ORF1 and ORF3, and an ORF2 disrupted 
by a neomycin gene engineered into the VP1‐encoding region (thus blocking expression of intact VP1). 
Self‐replicating and stably expressed following transfection into cell lines of human (Huh-7) or hamster 
(BHK21) origin, the replicon has proven useful for the study of HuNoV genome replication and 
screening of antiviral compounds (Chang and George, 2007; Rocha-Pereira et al., 2014).  
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The RNA replicon is complemented by VLP systems, in which expression of capsid protein 
VP1 results in the self-assembly of recombinant VLPs that are morphologically and antigenically 
indistinguishable from native HuNoV virions and consequently represent useful tools to study physical 
virion properties, antibody responses, and attachment factor interactions (Bertolotti-Ciarlet et al., 2002). 
Notwithstanding the utility of these two systems, the fact that the understanding of HuNoV 
biology has lagged behind that of other positive strand RNA viruses has been, in great part, due to the 
difficulties historically associated with robust in vitro HuNoV propagation (Duizer et al., 2004; Lay et 
al., 2010); in turn, issues with HuNoV cell culture stem from the uncertainties still surrounding HuNoV 
tropism and the lack of a known (proteinaceous) entry receptor (see chapter 1.4.1).  
Recent data support a dual cell tropism of epithelial cells and nonepithelial cells of 
hematopoietic origin both in vivo (Karandikar et al., 2016) and in vitro (Wobus, 2018) and illustrate a 
complex interplay with the host microbiome (Jones et al., 2014; Walker and Baldridge, 2019). Currently, 
two different HuNoV cell culture systems successfully capitalise on this dual tropism. 
The development of the in vitro BJAB human B cell line demonstrated that HuNoV (and 
MuNoV) can either infect B cells directly or in a coculture system in which the virus must cross a 
confluent epithelial monolayer to access underlying B cells; productive GII.4 HuNoV infection of B 
cells required the presence of the HGBA-expressing commensal bacteria (or free synthetic HBGA), 
identifying them as a stimulatory cofactor for bridging NoV attachment to and infection of B cells (Jones 
et al., 2015, 2014). This and other available data directed the development of a working model for NoV 
intestinal infection whereby NoVs bind to specific glycans expressed on the surface of members of the 
gut microbiota and/or enterocytes and are then transcytosed across the polarized intestinal epithelial 
barrier to gain access to their target immune cells (Karst, 2015b; Karst and Wobus, 2015). Notably, this 
model provides an explanation for how NoVs may achieve co-infection of host cells in conditions when 
the number of cells far outweighs that of virions; multiple genetically distinct virions can be effectively 
concentrated by binding to the surface of a single bacterium, thereby increasing the opportunity for co-
infection (Erickson et al., 2018; Jones and Karst, 2018). While the technical simplicity and use of a 
commonly used cell line are strengths of the BJAB assay, current drawbacks are the modest level of 
viral replication and varying reproducibility. 
In a technically more complicated approach, but with more robust infection levels overall, 
cultivation of multiple HuNoV strains has recently been demonstrated in stem cell–derived, human 
intestinal enteroid (HIE) cultures (epithelial mini guts) which recapitulate the multicellular, 
physiologically active human intestinal epithelium (Estes et al., 2019; Ettayebi et al., 2016). Grown from 
single multipotent stem cells of the human intestinal crypts (isolated from endoscopic biopsies), HIEs 
can be maintained continuously as three-dimensional cultures. Differentiation into distinct mature cell 
types present in the epithelium, such as absorptive enterocytes, multiple secretory cells (Paneth cells, 
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goblet cells, enteroendocrine cells, and tuft cells), and the M cells of Peyer’s patches  can be achieved 
by modifying culture conditions (Sato et al., 2011, 2013). Propagation (and limited passaging) of 
HuNoVs in enterocytes of differentiated HIEs (either three-dimensional or trypsinised and seeded into 
monolayers) has been shown to be dependent on HBGA expression in a strain-dependent manner 
(secretor-negative HIEs are permissive to GII.3, but not GII.4 replication); in addition, bile acids have 
been shown to be required for productive infection of certain strains (GI.1, GII.3, and GII.17), but bile 
is not necessary for cultivation of HuNoV GII.4/Sydney. The expense and complexity of the HIE system, 
relatively low sensitivity of the cultures to infection, issues with sustained passaging, and the unresolved 
basis for strain specific replication requirements remain challenges faced in the ongoing enhancement 
of HuNoV HIE cultures (Estes et al., 2019). 
Different in vivo and in vitro HuNoV assays have all provided invaluable tools to dissect the 
NoV life cycle. However, there is still a lack of detailed understanding of NoV replication and significant 
questions remain unanswered due to the technical limitations of many of these experimental systems. 
 
1.9.3 The murine norovirus - an in vivo and in vitro human norovirus surrogate 
The genetically and biologically closely related murine norovirus (MuNoV) combines the 
advantages of easy in vivo infection of a cost-effective, genetically tractable, bona-fide native host (Karst 
et al., 2003), efficient and robust in vitro culture systems (Wobus et al., 2006, 2004), and availability of 
tools for genetic manipulation (Arias et al., 2012a, 2012b; Yunus et al., 2010), and thus remains the 
model of choice to study both the host response to NoV infection and basic aspects of NoV biology. 
Caveats to the model include differences between HuNoV and MuNoV carbohydrate attachment 
factors and proteinaceous receptors (see chapter 1.4.1), the fact that HuNoVs replicate in intestinal 
enterocytes, a cellular tropism that MuNoV does not seem to share, and the typically asymptomatic 
nature of MuNoV infections in wild-type mice. In vivo MuNoV infections of adult immunocompetent 
and immunocompromised mice as well as those of neonatal mice are described in chapter 1.5.3. The 
adult in vivo models have long yielded valuable information concerning the biology of a NoV in its 
natural host (Wobus et al., 2006). The newly described model of NoV diarrhoea in which key clinical 
features of HuNoV disease are mirrored in MuNoV-infected neonatal mice will open up new avenues 
of research and the finding that disease severity is  regulated by viral genetics (MNV-3 and MNV-CR6 
cause a reduced incidence of diarrhoea relative to MNV-1) will facilitate identification of viral virulence 
determinants (Roth et al., 2020). 
Until very recently, MuNoVs were the only cultivable NoVs, replicating efficiently and to high 
titres in cultured bone marrow-derived murine macrophages (RAW264.7 cells) (Wobus et al., 2006, 
2004) and murine-derived microglial cells (BV-2 cells) (Cox et al., 2009) as well as B cells (M12 and 
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WEHI-231), where peak titres are reached one day later than in RAW264.7 macrophages (Jones et al., 
2014).  
The panel of techniques described to study MuNoV biology (Hwang et al., 2014) includes both 
DNA-based and RNA-based reverse genetics systems (Arias et al., 2012b). The DNA-based system is 
implemented in Study 2 of the Experimental Section of this thesis. Briefly, complementation in baby 
hamster kidney cells constitutively expressing the bacteriophage T7 RNA polymerase by a helper 
fowlpox virus encoding for T7 RNA polymerase allows transcription of an infectious plasmid containing 
MuNoV cDNA under control of a truncated T7 polymerase promoter (pT7: MNV 3’ Rz), expression of 
the viral RNA, and subsequent recovery of infectious virus (Arias et al., 2012a) (Figure 7). A more 
sensitive RNA-based approach allows efficient recovery of infectious MuNoV from cDNA via in vitro 
transcription, in vitro capping and subsequent transfection into permissive RAW264.7 or BV2 cells 
(Yunus et al., 2010). 
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2. Molecular evolution of noroviruses 
 
2.1 General concepts of RNA virus evolution 
 
RNA viruses, particularly those of the positive-strand Baltimore class IV, account for the 
majority of the virome diversity in eukaryotes (Koonin et al., 2015); RNA viruses pose major threats to 
human and animal health and number prominent agents of emerging and re-emerging infectious diseases  
(Holmes, 2010a; Woolhouse, 2002). A catalogue of all known human-infective RNA virus species 
comprises over 200 listings, is thought to be by no means complete, and remains subject to continuous 
revisions (Woolhouse and Brierley, 2018).  
The variability within the RNA virosphere originates with the reliance of its constituents on the 
error prone RdRp, the viral hallmark protein that is universally conserved in RNA viruses (Koonin et 
al., 1993). The low-fidelity RdRp both introduces mutations (genetic drift) and mediates recombination 
between nascent RNA genomes (genetic shift). The viral diversity thus intrinsically produced is then 
modulated by extrinsic evolutionary forces, including random genetic drift (driven by frequent 
bottlenecking events) and natural selection (episodes of strong purifying pressure) (Grenfell et al., 2004).  
2.1.1 Point mutation accumulation of RNA viruses 
Mutations in viral genomes may originate from a range of sources such as spontaneous nucleic 
acid damage (all viruses), diversity-generating retro-elements (encoded by prokaryotic DNA viruses), 
and editing of the genetic material by host-encoded proteins (enzyme-driven hypermutation acts on a 
number of RNA viruses) (Sanjuán and Domingo-Calap, 2016). Intrinsic polymerase fidelity, the ability 
to incorporate the correct base and exclude incorrect bases from the active site during synthesis, is the 
primary determinant of genetic diversity (Sanjuán and Domingo-Calap, 2016). While error frequencies 
between viral polymerases are comparable prior to exonuclease correction, viral mutation rates are 
modulated by the ability of a virus to correct mismatches via polymerase-associated proofreading and/or 
post-replicative repair, a characteristic typically encoded by DNA viruses. Low-fidelity RNA virus 
RdRps lack exonuclease activity and consequently intrinsically misincorporate at higher frequencies 
(Smith, 2017) (exception among RNA viruses: viruses from the order Nidovirales encode a proofreading 
3′- to -5′ exoribonuclease (Ogando et al., 2019)). At 0.1 to 1.0 mutations per genome per RdRp-mediated 
replication (Duffy et al., 2008), or 10−6 to 10−4 substitutions per nucleotide site per cell infection (s/n/c), 
average RNA virus mutation rates are several orders of magnitude higher than those of most DNA-based 
organisms (Peck and Lauring, 2018; Sanjuán, 2012).  
High mutation rates confer genetic plasticity to a viral population; “mutational fitness effects” 
may be neutral, beneficial or deleterious to the overall fitness of a given virus within a viral population 
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(Wargo and Kurath, 2012). Within the typically compact RNA virus genomes (notable exception: 
Nidovirales) that encode only a few proteins, even single nonsynonymous mutations can be sufficient 
to alter the structure or function of virus-encoded proteins (Borin et al., 2014; Elde, 2012). Synonymous 
mutations (which do not change encoded amino acids) may impact viral fitness via non-neutral epistatic 
effects influencing RNA stability and splicing (Draghi et al., 2010; Lauring and Andino, 2010) and silent 
tuning for increased adaptability (Chamary et al., 2006; Elde, 2012; Lauring et al., 2012; Wilke and 
Drummond, 2010). In RNA viruses, most mutations are deleterious or lethal and result in the generation 
of less-fit or non-replicative variants, and beneficial mutations are comparatively rare (Sanjuán et al., 
2004). Consequently, RNA virus populations commonly contain large numbers of defective RNAs or 
defective interfering particles, virus-like by-products of replication that carry deleterious mutations 
(typically large deletions). These degenerate non-viable particles may “interfere” with standard virus 
particles by competing for resources (Stauffer Thompson and Yin, 2010) but may also modulate the 
course of infection by acting as immune stimulants or immune decoys (Rezelj et al., 2018). The 
incorporation of deleterious mutations in an irreversible, ratchet-like manner is termed Muller’s ratchet 
and can lead to a rapid debilitation of viral fitness unless relieved by compensatory mechanisms (Muller, 
1964). 
RNA virus replication may be described as a balancing act between the generation of sufficient 
diversity on which natural selection can act and the maintenance of genetic integrity and infectivity 
(Smith, 2017). This is illustrated by the fact that alterations to intrinsic RdRp fidelity have been 
demonstrated to have a negative impact on viral fitness in complex environments (Bordería et al., 2016), 
suggesting that RNA virus mutation rates have been evolutionarily optimised. 
2.1.2 Selection and genetic drift of RNA viruses 
Within the epidemiological triad of host, agent, and environment, viruses are locked in a 
perennial arms race with their hosts as they attempt to comply with the biological imperative of genetic 
survival (of the fittest) (Hurst and Lindquist, 2000).  
The deterministic force of natural selection acts on the phenotypic diversity of mutant genomes 
in a viral population and drives viral populations as a whole towards increased overall viral fitness; 
positive selection drives fixation of beneficial mutations in a population, purifying selection removes 
deleterious reduced fitness mutants (Dolan et al., 2018).  
The stochastic influence of random genetic drift, the change of variant frequencies in a viral 
population which occurs as a result of sampling error from generation to generation, can lead to the 
fixation of neutral and deleterious mutations in finite populations (Gillespie, 2001). RNA viruses, which 
can experience significant fluctuation in their population sizes, are subjected to the strong influence of 
genetic drift when within-host and transmission bottlenecks mediate transient reduction of the number 
  Introduction 
  43 
of viral genomes and the ensuing population is derived from a small sample of the ancestral population 
(Gutiérrez et al., 2012; Li and Roossinck, 2004).  
Viral substitution rates, which describe the rate at which mutations become fixed within a 
population subsequent to selection and genetic drift, largely correlate with mutation rates. Thus, the high 
mutation rates of RNA viruses are mirrored in their mean nucleotide substitution rates of 10−4 to 10−3 
s/n/y (Duffy et al., 2008; Holmes, 2010a). 
The high evolutionary rates of RNA viruses are held to be inextricably linked to their typically 
short genomes, large population sizes, and their existence as viral quasispecies (Andino and Domingo, 
2015; Holmes, 2010a, 2009; Sanjuán et al., 2010).  
2.1.3 RNA viruses as viral quasispecies  
 
Building on classical population genetics, quasispecies theory seeks to explore the consequences 
of error-prone replication of simple RNA and RNA-like replicons and near-infinite population sizes for 
genome evolution (Eigen, 1993). More recently, quasispecies theory has been used to describe the 
mutant distributions that are generated upon replication of rapidly mutating RNA viruses at large 
population sizes (Andino and Domingo, 2015; Domingo, 2016, 1998; Domingo et al., 2012; Domingo 
and Perales, 2019; Lauring and Andino, 2010; Más et al., 2010). 
 
According to viral quasispecies theory, virus populations (mutant “spectra”, “clouds”, 
“swarms”) are depicted as collections of closely related viral genomes connected by a network of single 
mutations which surround a modal master or consensus sequence; variants are linked within the viral 
population through antagonistic and cooperative functional interactions and collectively contribute to 
the characteristics of the population (Andino and Domingo, 2015; Domingo et al., 2012; Holmes, 
2010b). The target of selection is the population as a whole, wherein variant distributions can swiftly 
shift and adapt to altered selective conditions by virtue of the expansive repertoire (or reservoir) of 
potentially beneficial mutations. The effect of deleterious mutations, which result in low individual 
fitness variants or defective interfering particles, can be relieved through complementation (Segredo-
Otero and Sanjuán, 2019; Vignuzzi et al., 2006), cooperation (Shirogane et al., 2016), and, notably, 
recombination between different viruses (Muller, 1964).  
Viral quasispecies theory has been extended to include not only the effects of point mutation 
accumulation but also recombination, which can buffer viral populations against deleterious and lethal 
mutations, prevent extinction of advantageous mutants during selective sweeps, combine co-circulating 
adaptive mutations to generate new variation that enhances virus fitness, but may also push a 
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quasispecies over a critical error threshold (Andino and Domingo, 2015; Boerlijst et al., 1996; Domingo 
et al., 2012).  
2.1.4 RNA virus recombination – definitions and mechanisms of viral genetic shift 
 
The concept of recombination prevalent in evolutionary genetics describes the complex 
molecular process by which a fragment of DNA is reciprocally exchanged between homologous 
chromosomes in the context of sexual reproduction in eukaryotes (exchange of genetic material between 
chromatids in the first meiosis division) (Posada et al., 2002).  In prokaryotes and viruses, 
recombination, more aptly described as lateral gene transfer or gene conversion, involves nonreciprocal 
replacement or addition of genome sequences rather than exchange (Pérez-Losada et al., 2015; Posada 
et al., 2002).  
 
Viral recombination occurs when at least two viruses infect the same host cell and exchange 
genetic sequences; less frequently, recombination may occur between viral and cellular sequences 
(Becher and Tautz, 2011). Between two (or more) RNA viruses, recombination can occur either via a 
replicative copy-choice mechanism or via non-replicative breakage and re-joining of genome fragments; 
both processes can theoretically result in homologous recombination involving the same site in both 
parental strands or non-homologous (illegitimate) recombination at different sites of the donor 
molecules (Galli and Bukh, 2014). Consequently, irrespective of the underlying recombination 
mechanism, homologous recombinants have the same genome architecture as their parental viruses, 
whereas nascent non-homologous recombinants bear atypical structures including deletions, insertions, 
or duplications (Galli and Bukh, 2014; Worobey and Holmes, 1999).  
 
Focusing on the underlying mechanisms at play, three classes of replicative RNA recombination 
have been described (Nagy and Simon, 1997); accordingly, recombination events may be classed as 
similarity-essential (base-pairing dependent; class I), similarity-nonessential (base-pairing independent; 
class II), and similarity-assisted (base-pairing assisted; class III). For class I recombination, sequence 
similarity between parental RNAs is held to facilitate annealing between nascent and acceptor RNAs 
within the complementary region and is described as the major determinant of a recombination event. 
For class II recombination, sequence similarity between parental RNAs is not a requirement and 
recombination depends on RNA features other than base-pairing (e.g. RdRp binding sequences, RNA 
secondary structures, and heteroduplex formation between parental RNAs) which may bring parental 
RNAs into proximity and mediate template-switching by stalling the viral RdRp. Class III recombination 
combines features of both class I and II recombination in that both base-pairing and additional RNA 
features influence the occurrence of recombination events (Figure 8). 
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The replicative copy-choice model of recombination typically (but not exclusively) depends on 
sequence similarity and mostly results in homologous recombination (if the viral polymerase continues 
to copy the new strand precisely where it left the old one); it is generally accepted to be the prevalent 
recombination mechanism in RNA viruses (Simon-Loriere and Holmes, 2011; Worobey and Holmes, 
1999). Following this model, a mid-replication switch of the viral polymerase and the replication 
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complex from “donor” to “acceptor” template during synthesis of the nascent strand results in a chimeric 
RNA that contains fragments of both parental templates (Galli and Bukh, 2014). 
 
The non-replicative mechanism of recombination describes self-ligation or host-factor-mediated 
joining of genetic fragments randomly cleaved through external influences such as physical shearing, 
electromagnetic radiation damage, and the activity of cellular endonucleases or cryptic ribozymes. 
Breakage and re-joining may occur between fragments of the same virus, amongst different viruses, and 
also between viral and cellular molecules, and more frequently results in non-homologous than 
homologous recombination (Galli and Bukh, 2014). Non-replicative recombination has been 
demonstrated for a number of positive sense single-stranded RNA viruses (Büning et al., 2017; Gallei 
et al., 2004; Galli and Bukh, 2014; Lowry et al., 2014). Proposed models for replicative and non-
replicative NoV recombination, but which may also serve to illustrate RNA virus recombination in a 
wider context, are shown in Fig. 1 of the review on NoV recombination that comprises chapter 2.3 of 
this thesis (Ludwig-Begall et al., 2018). 
 
Reassortment (or shuffling), a particular type of recombination unique to segmented or 
multipartite viruses (Sicard et al., 2016), can interchange discrete genome segments of co-infecting 
parental viruses; without involving intramolecular crossovers, entire genome segments of different 
origins are packaged into progeny viruses during viral replication, thereby giving rise to novel segment 
combinations (Pérez-Losada et al., 2015). Reassortment is frequently observed in segmented DNA and 
RNA viruses (Nelson et al., 2008; Thiry et al., 2005), however since it does not apply to monopartite 
NoVs which experience recombination in sensu stricto, the mechanism is not further discussed in the 
context of this thesis. 
 
2.1.5 RNA virus recombination frequencies 
 
Recombination frequencies are known to vary extensively amongst different RNA viruses; 
while large-scale comparative studies of RNA virus recombination rates are as yet lacking, significant 
variation has been reported both for the intrinsic rates of replicative and non-replicative RNA virus 
recombination prior to selection, as well as recombination rates that can be inferred at the population 
level. The former are typically measured in vitro via single-cycle assays in co-infected cells, population 
level estimations are typically based on sequence analysis and necessarily exclude deleterious 
recombinant forms that have been removed by purifying selection (Simon-Loriere and Holmes, 2011).  
Recombination is frequent in retroviruses, notably in the human immunodeficiency virus where 
recombination rates, at approximately two to three recombination events per genome per virus 
replication cycle or 1.38 x 10-4 to 1.4 x 10-5 recombination events/adjacent sites/generation, may exceed 
those of mutation (Jetzt et al., 2000; Shriner et al., 2004). Such high recombination rates probably reflect 
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mechanistic aspects of retrovirus biology and genome architecture; specifically, their pseudodiploidy 
may facilitate recombination when two RNA molecules are packaged into the same virion, the physical 
proximity thus increasing the likelihood of template switching which is, in itself, an intrinsic component 
of the retrovirus replication strategy (Simon-Loriere and Holmes, 2011). Meanwhile, negative sense 
RNA viruses only infrequently experience recombination (Chare et al., 2003). Reasons for low negative 
sense RNA virus recombination rates remain to be fully elucidated but may include both ecologic and 
mechanistic constraints; their low recombination rates have been tentatively linked to the presence of 
the RNA-bound ribonucleoprotein complex which may affect the ability of the RNA polymerase to 
switch templates during replication (Chare et al., 2003). In positive sense RNA viruses, recombination 
occurs at highly variable frequencies between different virus families; recombination is frequently 
observed in the Caliciviridae, Picornaviridae and Coronaviridae (vertebrate viruses; in the latter, 
recombination is likely facilitated by discontinuous transcription involving jumps of the replication-
transcription complex during minus strand RNA synthesis) (Desselberger, 2019; Lin et al., 2019; 
Simmonds, 2006), Bromoviridae and Potyviridae (plant viruses), but appears to be non-existent in the 
Leviviridae (bacteriophages), Barnaviridae, and Narnaviridae (mycophages) (Bentley and Evans, 2018; 
Simon-Loriere and Holmes, 2011). In addition, rates may also vary significantly between different 
genera of the same family. Thus, the incidence of recombination varies amongst the four genera of the 
Flaviviridae, where recombination events are easily detected in pestiviruses (Becher and Tautz, 2011; 
Büning et al., 2017), pegiviruses (Zhang et al., 2019), the hepacivirus, hepatitis C virus (Galli and Bukh, 
2014), and certain mosquito-borne flaviviruses (Durães-Carvalho et al., 2019), but are rarely reported 
in any of the tick-borne flaviviruses (Bentley and Evans, 2018; Norberg et al., 2013).  
The range of recombination rates that characterises RNA viruses may be held to either reflect 
purely mechanistic features of particular viral ecologies or genome architectures, or may be attributed 
to certain advantages of recombination over asexual evolution and the fact that natural selection may 
favour specific genetic variants produced by recombination (Holmes, 2009; Simon-Loriere and Holmes, 
2011). A dissection of the various checkpoints or steps that give rise to a recombinant a viral RNA, and 
ultimately a viable recombinant RNA virus, illustrates how drivers and constraints at each stage can 
determine whether a recombination event may be achieved for a given virus (Worobey and Holmes, 
1999). 
2.1.6 RNA virus recombination checkpoints 
 
For the generation of a recombinant viral RNA, and ultimately a viable recombinant RNA virus, 
several requirements must be met (Galli and Bukh, 2014; Worobey and Holmes, 1999). Five steps or 
checkpoints must be successfully completed in vivo to generate a viable, replicating recombinant RNA 
virus following the classical copy-choice model of replicative recombination; four steps are necessary 
to obtain the same result via non-replicative recombination (Figure 9). 
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The first step necessarily preceding any recombination event is the simultaneous infection of a 
host with at least two parental strains (or clonal within-host replication allowing for subsequent 
recombination between nascent progeny viruses). Co-circulation of different viral strains in the same 
geographic area and within the same risk population are prerequisites to synchronous host co-infection. 
An overlap in space, if not in time, may nevertheless enable simultaneous infection of a host, provided 
superinfection by a secondary virus is not prevented by the host immune system and the primary virus 
has not been cleared before the event (Worobey and Holmes, 1999). 
 
Once a host has been successfully co-infected, the second step is co-infection of a single target 
cell. The uptake of multiple viruses into a single cell is dependent both on the quantity of co-circulating 
viruses, the mode of their uptake (Erickson et al., 2018), and on factors that may limit consecutive entry 
of more than one virus particle per cell in a process known as superinfection exclusion. Superinfection 
exclusion is defined as the ability of an established virus to prevent a secondary infection by the same 
or a closely related virus (Folimonova, 2012); the primary infecting virus may render cells refractory to 
subsequent infection through interference at various stages of the replicative cycle of the secondary 
invader in a time-dependent manner. Viral pre-and post-entry blocks have been described for a number 
of RNA viruses (Adams and Brown, 1985; Bergua et al., 2014; Bratt and Rubin, 1968; Claus et al., 
2007; Huang et al., 2008; Lee et al., 2005; Tscherne et al., 2007; Zhou et al., 2019), but may be overcome 
by certain strains after a period of adaptation (Lee et al., 2005; Webster et al., 2013; Zou et al., 2009).  
 
The third step to obtaining a recombinant virus can either consist of a step of non-replicative 
recombination or a combination of replication and template switch (step four) between two co-infecting 
viruses within a cell. Co-localisation to the same subcellular region within said cell is necessary for 
interaction between viral genomes via either mechanism; co-occupancy of replication complexes is a 
prerequisite to recombination via the replicative pathway. Specific features of the viral genome and 
replicative proteins may further advance or hinder copy-choice recombination. Thus, the distribution of 
recombination junctions is frequently biased towards regions of sequence identity between RNA 
templates, the presence of tertiary genome structures is held to expedite replicative recombination, and 
the fidelity of the polymerase itself plays a role in determining how often particular genomes recombine 
(Bentley and Evans, 2018; Worobey and Holmes, 1999).  
 
By whichever way a recombinant viral genome is generated, it is by no means a foregone 
conclusion that the process will result in a replicating recombinant RNA virus. Any given recombination 
event, switching out large genome segments in a nascent virus, presents a significant modification. It 
follows that initial imprecise recombination events (e.g. introduction of mutations or faulty epistatic 
interrelationships between the parts of an incipient recombinant) present an evolutionary bottleneck that 
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can result in the generation of non-functional genome chimeras (defective or defective interfering 
RNAs) or recombinant viruses of reduced replicative fitness. If recombinants are not able to function at 
the same level as their parental strains or do not possess selective advantages over their progenitors, it 
is unlikely that they will survive in a viral population (Lowry et al., 2014; Sackman et al., 2015). Studies 
in various RNA viruses have shown that circulating recombinants probably only represent a subset of 
those that are actually generated, and are the ones that are maintained in the viral population after a 
rigorous functional selection, having bypassed this fifth and final step of successful RNA virus 
recombination (Bagaya et al., 2017; Banner and Mc Lai, 1991; Lowry et al., 2014). 
 
A conceptual model illustrating RNA virus recombination checkpoints is shown in Figure 9 
(and is, with corresponding adaptations, reprised in Figure 3 of the review on NoV recombination that 
comprises chapter 2.3 of this thesis (Ludwig-Begall et al., 2018)). 
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2.1.7 Consequences of RNA virus recombination  
 
Successful recombination, whether it represents an accidental by-product of virus biology 
(reflecting breakage and joining (non-replicative) and/or association and dissociation of RNA template 
and replication complex (replicative)), or a key adaptive and evolutionarily selected process, may 
profoundly influence an individual virus and a virus population as a whole.  
  Introduction 
  51 
 
A single recombination event can switch out entire genome sections and simultaneously transfer 
multiple mutations previously incorporated into a genomic region; deleterious mutations can be purged 
via this process (an escape from Muller’s ratchet) and advantageous genetic combinations may unlink 
from deleterious backgrounds and be spread at a rate unattainable by purely clonally reproducing 
organisms (Bentley and Evans, 2018; Simon-Loriere and Holmes, 2011).  
 
The extensive genetic changes achievable through successful recombination can result in rapid 
and extreme changes in virus phenotype, allowing for antigenic shifts (Hahn et al., 1988; Malim and 
Emerman, 2001), pathogenesis and fitness modifications (including the facilitated spread of drug-
resistant mutants) (Moutouh et al., 1996), and changes in receptor or even host tropism (Jackwood et 
al., 2010; Li et al., 2020).  
 
Various prominent human pathogenic disease outbreaks have been linked to recombination 
events. Thus, bouts of vaccine-derived paralysis have been linked to recombination between live 
attenuated poliovirus vaccine strains and circulating enterovirus C species (Bentley and Evans, 2018; 
Kew et al., 2002); the three most pathogenic human coronaviruses (SARS, MERS, and most recently 
SARS-2) are the result of recombination among coronaviruses (Graham and Baric, 2010; Li et al., 2020). 
Consequently, the potentially dire fallout of viral recombination calls for an improved insight into and 
closer monitoring of these processes.   
 
2.2 Norovirus point mutation accumulation 
 
2.2.1 Human norovirus mutation rates and sources of point mutation 
 
The NoV RdRp, a key enzyme for transcription and replication of the NoV genome, shares 
functional and structural features with other RNA virus polymerases (Deval et al., 2017). In vitro RdRp 
fidelity assays have been implemented to experimentally determine mutation rates of various HuNoV 
strains (Bull et al., 2010). These assays demonstrated overall mutation rates to lie within the range of 
those typically described for RNA viruses, but pinpointed strain-dependent differences. Globally 
predominant GII.4 strains had five- to 36-fold higher mutation rates (average of 7.95 x 10-4 substitutions 
per nucleotide site or 5.97 ±1.96 substitutions per genome replication event) compared to less frequently 
detected strains, GII.b (1.53 x 10-4 or 1.15 substitutions per genome replication event) and GII.7 (2.21 x 
10-5 or 0.17 substitutions per genome replication event).  
 
Recently, single-cycle viral replication of a Norwalk virus infectious cDNA clone transfected 
into human embryonic kidney cells yielded a mutation rate estimate of 1.5×10−4 s/n/c (Cuevas et al., 
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2016). Interestingly, a large fraction of NoV spontaneous mutations constituted U-to-C and A-to-G 
substitutions occurring as bouts of mutations in the same RNA molecule; such sequence changes are 
characteristic of adenosine to inosine editing (inosines subsequently base-pair with cytosines) by 
double-strand RNA-dependent adenosine deaminases (ADARs) (Samuel, 2012), suggesting that host-
driven extrinsic NoV hyper-mutation acting on double-stranded replication intermediates may be a 
source of NoV diversity comparable to intrinsic viral RdRp fidelity. In depth analysis of NoV 
spontaneous mutations in clinical GII.4 samples supported the hypothesis that hyper-mutation may 
reflect a relevant mutational process in NoVs (Cuevas et al., 2016). 
 
2.2.2 Evolutionary rates of human noroviruses 
 
Early bioinformatics analysis of published ORF2 sequence data revealed strain dependent 
differences in NoV evolutionary rates, estimating 1.7-fold higher average rates of evolution within GII.4 
capsid sequences (3.9 x 10-3 n/s/y)  than other NoVs (GII.3, GII.3[Pb], GII.7 with 1.9 x 10-3, 2.4 x 10-3, 
and 2.3 x 10-3 n/s/y, respectively) (Bull et al., 2010). Higher ratios of nonsynonymous to synonymous 
amino acid changes in GII.4 NoV capsids were held to indicate that GII.4 strains experience faster rates 
of antigenic drift than other NoV strains as a probable consequence of their higher RdRp mutation rates 
(Bull et al., 2010). Nonsynonymous mutations for NoV GII.4 and all other analysed genotypes (albeit 
at lower numbers) were shown to cluster to common structural surface-exposed residues of the 
hypervariable P2 capsid domain, corresponding to known HBGA-binding targets and hypervariable 
GII.4 “evolution hotspots” (Lindesmith et al., 2008), suggesting that these sites are likely to be subject 
to immune-driven selection (Bull et al., 2010).  
 
Other long-term evolutionary analyses of archival NoV sequences have calculated similar 
population-level evolutionary rates for GII.4 VP1 capsid sequences (4.3 x 10-3 n/s/y) and have identified 
preferential sites for evolution under positive selection to be located in the VP1 shell domain as well as 
P2 (Karin et al., 2009; Mori et al., 2017). However, in contrast to previous observations, evolutionary 
rates of various non-GII.4 genotypes, e.g. GII.3 VP1 (4.16 x 10-3 n/s/y) (Boon et al., 2011), GII.2[P2] 
(1.75 x10-3 n/s/y) or GII.2[P16] (2.37 x 10-3 n/s/y) (Tohma et al., 2017), have been estimated to be close 
to those of GII.4 strains. Differences in mutation rates may provide higher diversity at a given time (e.g. 
after a recombination event) and so confer an advantage to GII.4 strains; however, they seem to have a 
limited impact on overall NoV evolutionary rates. Strain-dependent differences of NoV evolutionary 
patterns are thus not entirely attributable to differences in viral RdRp fidelity and remain to be fully 
elucidated.  
 
Full-genome deep sequencing analyses have revealed that evolutionary rates are not uniform 
across the NoV genome, with surface- and immune-exposed regions experiencing more variation than 
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less malleable sections; correspondingly, ORF2 (VP1) and ORF3 (VP2)-specific rates are typically 
higher than those reported for ORF1 (NS). Within ORF1, regions encoding NS1/2 and NS4 have been 
shown to exhibit the highest levels of change (Cotten et al., 2014; Hasing et al., 2016). 
 
Overall NoV evolutionary dynamics at inter-host population levels may differ from intra-host 
dynamics where, subsequent to transmission typically characterised by a strong genetic bottleneck,  
evolutionary rates fluctuate by several orders of magnitude dependent on the host immune status (Bull 
et al., 2012; Hoffmann et al., 2012; Karst and Baric, 2015) (as described in chapter 1.6.6).  
 
2.2.3 Impact of human norovirus diversification via point mutation accumulation 
 
The epochal emergence of GII.4 variants is commonly ascribed to the accumulation of novel 
VP1 GII.4 amino acid mutations (linear evolution with intermediate periods of stasis), while non-GII.4 
genotypes experience limited changes and can persist for decades with minimal VP1 modification as 
so-called static genotypes (Boon et al., 2011; Mori et al., 2017; Parra, 2019; Parra et al., 2017).  
 
The emergence of both GII.4 and non-GII.4 viruses has been linked to changes in the viral 
RdRp, highlighting it, and potentially other non-structural proteins, as drivers of NoV evolution. Thus, 
the emergence of certain GII.4 variants (since their establishment as prevalent genotype in the mid-
1990s) has been associated with mutations in the GII.4 RdRp gene (Lopman et al., 2004) or acquisition 
of a new viral polymerase via recombination (the genetic diversity of GII.4 variants due to 
recombination is discussed in chapter 2.3) (Cannon et al., 2017; Parra, 2019). Both the predominance of 
re-emerging (2016-2017) (Ao et al., 2018; Tohma et al., 2017) recombinant GII.2[P16] viruses (Parra 
et al., 2017; Tohma et al., 2017) and GII.17[P17] viruses  between 2013 and 2015 (Parra and Green, 
2015) have been putatively associated to substitutions in the viral RdRp.  Notably, single HuNoV RdRp 
point mutations have been experimentally demonstrated to affect replication kinetics (Bull et al., 2010). 
 
Norovirus diversification and emergence is thus associated (in varying measure) with changes 
to two regions of the NoV genome, non-structural protein-encoding ORF1 and VP1-encoding ORF2. 
Recombination events can create chimeric viruses to generate new recombinants and further contribute 
to NoV strain diversification by combining and modifying existing mutational profiles (discussed in 
chapter 2.3).  
 
2.2.4 Murine norovirus evolution via point mutation accumulation 
 
In vitro mutation rates have been inferred for representative genome regions of MuNoV isolate 
MNV1-CW1 (Mauroy et al., 2017). Mutation rates were shown to not significantly differ between 
  Introduction 
  54 
regions encompassing partial coding sequences for NS1/2, NS5, NS6, and NS7 within ORF1, where 
they were within the same range as those reported for various HuNoV strains, but were estimated to be 
at least one order of magnitude higher for partial ORF2, 3 and 4 sequences (Mauroy et al., 2017). 
Interestingly, the existence of defective RNAs or defective interfering particles, commonly associated 
with the population dynamics of error-prone virus replication (Stauffer Thompson and Yin, 2010), was 
indicated by diverging infectious NoV virus titres and genomic copy values determined during MuNoV 
serial passaging (Mauroy et al., 2017).  
  
Highlighting the importance of point mutation as an evolutionary mechanism for NoVs, a single 
point mutation in NS1/2 (changing aspartic acid to glutamic acid) has been shown to dramatically alter 
the biological behaviour of a MuNoV, rendering non-persistent MNV1-CW3 persistent and causing an 
increased growth of CW3 in the proximal colon, a tissue reservoir of MuNoV persistence (Borin et al., 
2014; Nice et al., 2013). 
 
Furthermore, in vivo assays have shown that single point mutations modulating MuNoV RdRp 
fidelity may affect MuNoV pathogenesis; Arias et al. demonstrated a high-fidelity MNV-3 NS7 active-
site mutant to exhibit delayed replication in vivo (but not in vitro) and reduced transmission between 
hosts, suggesting that the generation of sufficient genetic diversity (via a low-fidelity RdRp) may be  
linked to efficient intra-host virus transmission (Arias et al., 2016). Conversely, artificially increased 
mutagenesis above the inherently high mutation rates of NoVs has been shown to lead to extinction of 
MuNoV populations (Arias et al., 2014), highlighting the NoV RdRp as an important target for the 
development of anti-noroviral therapies (see also chapter 1.8.1) (Rocha-Pereira et al., 2016). 
 
2.3 Norovirus recombinants: recurrent in the field, recalcitrant in the lab – A scoping review 
of recombination and recombinant types of noroviruses 
 
Chapter 2.3 of this thesis was published as a review article in the Journal of General Virology 
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Recombination and the accumulation of point mutations are key mechanisms in the evolution 
and diversity of NoVs. Increasing evidence indicates that recombination shapes NoV pathogenesis and 
fitness and drives the evolution of emerging HuNoV strains; new recombinant NoV types are 
continuously described in the context of sporadic cases and field outbreaks (Ludwig-Begall et al., 2018). 
The publication “Experimental evidence of recombination in murine noroviruses” (Mathijs et 
al., 2010), described the in vitro isolation of an infectious recombinant NoV. Recombinant MuNoV 
RecMNV was isolated following co-infection of RAW264.7 cells with two parental homologous 
MuNoV strains CW1 and WU20 in an infectious centre assay. While demonstrating a significantly lower 
in vitro replicative fitness than either of its parental strains, RecMNV remains one of its kind, to date 
constituting the only proven infectious experimental NoV recombinant (Mathijs et al., 2010, 2016).  
The 2018 Journal of General Virology review, “Norovirus recombinants: recurrent in the field, 
recalcitrant in the lab” (Ludwig-Begall et al., 2018), which compounds chapter 2.3.1 of this thesis, 
provides an overview of advances on the subject of NoV recombination and outlines the seeming 
discrepancy between the sheer quantity of naturally occurring NoV recombinants and the paucity of 
information and difficulties associated to NoV recombination as studied in the lab. Several putative 
drivers and constraints at various checkpoints of NoV recombination are identified in a conceptual 
model (see also Figure 10). Following this, host coinfection, single cell coinfection, and recombination 
must be accomplished to generate a recombinant NoV RNA; incipient recombinant viruses must then 
survive a process of functional selection to be maintained in the viral population. Figure 8 of this thesis 
recapitulates the NoV recombination checkpoints and attributes a colour code to indicate the level of 
confidence associated with their drivers and constraints; the particular drivers and constraints of NoV 
recombination investigated in the context of experimental sections 1 and 2 of this thesis are highlighted. 
Host coinfection may be dependent on spatial and temporal overlap of strain-distributions; cell 
coinfection, the ultimate prerequisite to viral recombination (Worobey and Holmes, 1999), depends on 
factors influencing the within-host distribution of viruses to target cells. True coinfection of cells is 
likely to be a rare event under natural conditions and delayed secondary infections are a more probable 
occurrence. In the event of an asynchronous infection, the uptake of multiple viruses into a single cell 
is dependent on factors that may limit consecutive entry of more than one virus particle per cell in a 
process known as superinfection exclusion. Superinfection exclusion is defined as the ability of an 
established virus to prevent a secondary infection by the same or a closely related virus (Folimonova, 
2012); the primary infecting virus may render cells refractory to subsequent infection through 
interference at various stages of the replicative cycle of the secondary invader in a time-dependent 
manner. Viral pre-and post-entry blocks have been described for a number of RNA viruses (Adams and 
Brown, 1985; Bergua et al., 2014; Bratt and Rubin, 1968; Claus et al., 2007; Huang et al., 2008; Johnson, 
2019; Lee et al., 2005; Tscherne et al., 2007; Zhou et al., 2019). 
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The first part of this thesis (Study 1) is dedicated to examining how different parameters of co- 
and superinfection may influence the composition of a nascent mixed viral quasispecies and investigates 
whether superinfection exclusion between two homologous MuNoV strains may play a role in 
preventing NoV co-infection in vitro; importantly, superinfection exclusion has remained hitherto 
unexplored in NoV biology.  
Recombination, while conferring selective advantages to a nascent recombinant virus on a 
population level under in vivo immune pressures, can entail great modifications in a single viral genome, 
potentially eliciting a replicative fitness cost, which must be compensated via the adaptive capacity of a 
recombinant virus.  
The second part of this thesis (Study 2) aims to characterise the adaptive capacity of in vitro 
generated RecMNV, thus investigating how the accumulation of point mutations through successive 
viral passaging can compensate for replicative fitness losses. The work, entitled “Replicative fitness 
recuperation of a recombinant murine norovirus – in vitro reciprocity of genetic shift and drift” (Ludwig-
Begall et al., 2020), has been published in Journal of General Virology.  
The aim of this thesis is to evaluate experimental conditions for and implications of MuNoV in 
vitro recombination. The insights thus gained will further a deeper understanding of the drivers and 
constraints of NoV recombination. 
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Preamble 
Viral recombination is a key mechanism in the evolution and diversity of noroviruses. In vivo, 
synchronous single-cell coinfection by multiple viruses, the ultimate prerequisite to viral recombination, 
is likely to be a rare event and delayed secondary infections are a more probable occurrence. Here, we 
determine the effect of a temporal separation of in vitro infections with the two homologous murine 
norovirus strains MNV-1 WU20 and CW1 on the composition of nascent viral populations. WU20 and 
CW1 were either synchronously inoculated onto murine macrophage cell monolayers (coinfection) or 
asynchronously applied (superinfection with varying titres of CW1 at half-hour to 24-hour delays). 24 
hours after initial co-or superinfection, quantification of genomic copy numbers and discriminative 
screening of plaque picked infectious progeny viruses demonstrated a time-dependent predominance of 
primary infecting WU20 in the majority of viral progenies. Our results indicate that a time interval from 
one to two hours onwards between two consecutive norovirus infections allows establishment of a 
barrier that reduces or prevents super-infection; this first demonstration of time-dependent viral 
interference for NoVs has clear implications for NoV epidemiology, risk assessment, and potentially 
treatment.   
An article describing the work presented in this chapter was published in the Multidisciplinary 
Digital Publishing Institute (MDPI) Open Access journal Viruses in May 2021 (Special Issue Series: 
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Replicative fitness recuperation of a recombinant murine 
norovirus – in vitro reciprocity of genetic shift and drift 
Experimental section 
Study 2: 






Noroviruses are recognised as the major cause of non-bacterial gastroenteritis in humans. 
Molecular mechanisms driving norovirus evolution are the accumulation of point mutations and 
recombination. Increasing evidence indicates that recombination influences NoV pathogenesis and 
fitness and contributes to the evolution of emerging HuNoV strains. For the generation of a viable 
recombinant NoV, several steps, namely host coinfection, single cell coinfection, RNA recombination, 
and functional selection, must be accomplished. Study 1 demonstrated how superinfection exclusion 
may interfere with the generation of recombinant NoV RNA by preventing cell-coinfection; Study 2 
now examines the next recombination checkpoint and addresses the issue of how incipient recombinant 
NoVs may survive a process of functional selection. Recombination can create considerable changes in 
a viral genome, potentially eliciting a fitness cost, which must be compensated via the adaptive capacity 
of a nascent recombinant NoV. A replicative fitness cost of the first in vitro generated WU20-CW1 
recombinant MuNoV, RecMNV, was reported by Mathijs et al., 2010. In this follow-up study, 
RecMNV’s capability of replicative fitness recuperation and genetic characteristics of RecMNV 
progenies at early and late stages of an adaptation experiment were evaluated. Replicative fitness regain 
of the recombinant was demonstrated via growth kinetics and plaque sizes differences between viral 
progenies prior to and post serial in vitro passaging. Point mutations at consensus and sub-consensus 
population levels of early and late viral progenies were characterised via next generation sequencing 
and putatively associated to fitness changes. To investigate the effect of genomic changes separately 
and in combination in the context of a lab generated inter-MNV infectious virus, mutations were 
introduced into a recombinant WU20-CW1 cDNA for subsequent DNA-based reverse genetics recovery 
(see Figure 11 for an overview of the experimental workflow). We thus associated fitness loss of 
RecMNV to a C7245T mutation and functional VP2 (ORF3) truncation and demonstrated individual 
and cumulative compensatory effects of one non-synonymous OFR2 and two synonymous ORF1 
consensus level mutations acquired during successive rounds of in vitro replication. Our data provide 
evidence of viral adaptation in a controlled environment via genetic drift after genetic shift induced a 
fitness cost of an infectious recombinant NoV. 
 
An article describing the work presented in this chapter was published in the Journal of General 
Virology in February 2020 and is reproduced below. 
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Graphical representation of the murine norovirus genome in which the positions of the four consensus-
level point mutations present in early and late recombinant murine norovirus progenies, RecE and RecL 
(GenBank accession numbers KU743153 and KU743152), are indicated.  
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The accumulation of point mutations (genetic drift) and viral recombination (genetic shift), and 
the interplay of these two pivotal evolutionary processes, are key mechanisms shaping the evolutionary 
dynamics and diversity of NoVs.  
 
Increasing evidence indicates that recombination modifies NoV pathogenesis and fitness and 
contributes to the evolution of emerging HuNoV strains (Ludwig-Begall et al., 2018). The emergence 
(or re-emergence) of NoV strains may have far-reaching practical consequences for routine diagnostics, 
typing, and epidemiological surveillance (difficulties generating sequence data from certain 
recombinant NoV strains were recently reported (Bonura et al., 2021)). NoV evolution in general, and 
recombination in particular, may further impact the development of vaccines (putatively necessitating 
regular updates of vaccine valencies) and the administration of antivirals (escape recombination may 
rescue virus populations from artificially-induced error catastrophe scenarios). It may also have 
considerable clinical implications should nascent strains display increased morbidity or be responsible 
for changes in disease severity.  
 
Despite its importance, the mechanisms involved in NoV recombination remain relatively 
understudied. The conceptual model presented in Chapter 1 (page 67) and in the Objectives of this thesis 
(page 77) outline the various steps, including their respective putative drivers and constraints, to be 
successfully bypassed for the generation of a viable recombinant NoV.  
 
While many predictive risk factors constitute confirmed aspects of NoV biology and their role 
in the context of recombination may thus reliably be inferred, others represent unknown variables that 
remain to be elucidated. In an update of the previous conceptual model, Figure 12 recapitulates the NoV 
recombination checkpoints, host coinfection, single cell coinfection, recombination, and functional 
selection, and attributes a colour code to indicate the level of confidence associated with their drivers 
and constraints based on perusal of pertinent literature and the experimental in vitro results obtained in 
this thesis.  
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Host coinfection may be dependent on spatial and temporal overlap of strain-distributions and 
host immune responses; Chapter 1.6.3 of this thesis describes how epidemiological analyses of 
contaminated foodstuffs (Mäde et al., 2013), waste-water treatment plants (Blanco Fernández et al., 
2011), environmental waters (da Silva Polo et al., 2016), and filter-feeding molluscs grown in effluent-
contaminated breeding grounds (Campos et al., 2017; Razafimahefa et al., 2019) have demonstrated 
overlapping NoV strain-distributions. The strain dependent differences in the induction of protective 
immune responses (Zhu et al., 2013), antigenic diversity and known lack of heterotypic cross-protection 
between certain NoV genogroups, genotypes and strains (Rockx et al., 2005a) that confound the 
determination of immunity duration (Cates et al., 2020) are discussed in chapter 1.6.4; chapter 1.6.6 
discussed the clinical analyses that have shown that patients can be infected by more than one NoV 
strain and that this is indeed a common occurrence in persistently infected individuals (Brown et al., 
2017). It appears that, owing to the particularities of NoV epidemiology and transmission, host 
coinfection thus presents a relatively easily surmountable barrier to NoV recombination. 
 
Cell coinfection, the ultimate prerequisite to viral recombination, depends on factors influencing 
the within-host distribution of viruses to target cells, thereby limiting or increasing the likelihood of 
cellular coinfections. In the case of NoVs, true coinfection may be facilitated either by synchronous 
uptake through consumption of contaminated food or drink (specifically bivalve molluscs carrying 
mixed virus loads) and/or promoted by other factors directing synchronous uptake of enteric viruses into 
both host and cell, such as multi-virion binding to intestinal bacteria (Erickson et al., 2018; Jones and 
Karst, 2018) (see also chapter 1.9.2). However, true coinfection of cells is likely to be a rare event and 
delayed secondary infections are typically a more probable occurrence.  
 
In the event of an asynchronous infection, the uptake of multiple viruses into a single cell is 
dependent on factors that may limit consecutive entry of more than one virus particle per cell in a process 
known as superinfection exclusion (chapter 2.1.6). Superinfection exclusion is defined as the ability of 
an established virus to prevent a secondary infection by the same or a closely related virus (Folimonova, 
2012); the primary infecting virus may render cells refractory to subsequent infection through 
interference at various stages of the replicative cycle of the secondary invader in a time-dependent 
manner. Viral pre-and post-entry blocks have been described for a number of RNA viruses (Adams and 
Brown, 1985; Bergua et al., 2014; Bratt and Rubin, 1968; Claus et al., 2007; Huang et al., 2008; Johnson, 
2019; Lee et al., 2005; Tscherne et al., 2007; Zhou et al., 2019); hitherto, NoVs have not been listed 
amongst them.  
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In Study 1, we determined the effect of a temporal separation of in vitro infections with the two 
homologous parental MuNoV strains MNV-1 WU20 and CW1 on the composition of MuNoV 
populations and demonstrated that a time interval from one to two hours onwards between two 
consecutive NoV infections allows establishment of a barrier that reduces or prevents superinfection; 
this first demonstration of time-dependent viral interference for NoVs has clear implications for NoV 
epidemiology, risk assessment, and potentially treatment.  
Viral interference has been shown to be an active, virus-controlled process in various RNA virus 
infections (Bratt and Rubin, 1968; Folimonova, 2012; Huang et al., 2008); examples for superinfection 
exclusion as directed by positive sense RNA viruses include the cleavage of incoming NS precursors by 
pre-existing proteases of primary infecting hepatitis C virus (Tscherne et al., 2007) or the dual pre- and 
post-entry blocks to superinfection launched by bovine viral diarrhoea virus within an hour post primary 
infection (Lee et al., 2005). Host-cell mediated processes may also intervene in viral interference, this both 
by induction of the intrinsic intracellular antiviral IFN system (see chapter 1.6.4) and/or activation of 
cellular RNA silencing. Type I and type II IFNs have been shown to inhibit translation of MuNoV proteins 
in RAW264.7 macrophage cells (Changotra et al., 2009). In analogy to an IFN pre-treatment of cells, is it 
possible that the priming of cellular IFN responses via primary infecting WU20 may have initiated 
interference with superinfecting CW1 in the context of the asynchronous infections performed in Study 1. 
While skewed input to output ratios of infectious viruses and genomic copies in Study 1 hinted at a role for 
DIPs or DI RNAs in mediating superinfection exclusion by induction of RNA silencing and the homology-
dependent degradation of incoming RNA molecules, these results must be interpreted cautiously since 
superinfection inhibition may be multifactorial and/or occur at different stages of the viral cycle. Future 
work will focus on the mechanics and temporal dynamics of NoV interference (pre- or post-entry mode of 
action analysis), thus aiming to further a deeper understanding of superinfection exclusion and ultimately 
its influence on NoV recombination both in vitro and in vivo.   
In a follow-up project to Study 1, utilisation of a lab-generated GFP-tagged (or FLAG-tagged) 
MuNoV infectious clone in co- and superinfection experiments may help elucidate how superinfection 
exclusion, which has been shown to be overcome by various viral mechanisms after a period of adaptation 
in vivo (Lee et al., 2005; Webster et al., 2013; Zou et al., 2009), plays a role in preventing NoV co-infection 
in vitro. Briefly, a reporter-tagged MuNoV will be generated via insertion of a green fluorescent protein 
(GFP) reporter gene into a plasmid containing wild type CW1 cDNA under control of a truncated T7 
polymerase promoter. Following a construction protocol for gene expression plasmids previously described 
for HuNoVs (Katayama et al., 2014), the GFP gene will be cloned into ORF1 between NS3 and NS4 of the 
MuNoV genome (this corresponds to a tolerated insertion site between the NTPase and 3A-like protein in 
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HuNoVs). The DNA-based reverse genetics system (Arias et al., 2012b; Yunus et al., 2010) described in 
chapter 1.9.3 of this thesis will be used for recovery of viable infectious viruses carrying the GFP tag. 
Following virus rescue, cultured murine macrophage cells will be infected synchronously or 
asynchronously with two homologous MuNoV strains (primary infection: WU20; superinfection: GFP-
tagged MNV1-CW1), using staggered superinfection times of 30 minutes to 24 hours to then trace 
superinfection exclusion by the simple exigency of localising GFP-tagged superinfecting virus via 
fluorescence microscopy. In circumvention of a possible entry block, synchronous and asynchronous 
transfection of MuNoV strains may also be investigated. 
While mixed populations of co- and superinfecting MuNoVs MNV-1 WU20 and CW1 were 
identified after plaque picking and amplification of viral progenies, not a single viable recombinant virus 
was isolated from the molecular screening process performed on a total of 864 plaque-picked infectious 
progenies (36 plaques x 24 conditions of co- or superinfection). Mathijs et al., 2010, previously 
demonstrated isolation of MuNoV recombinant RecMNV from an infectious centre assay involving mixed 
infections of WU20 and CW1 and screening of 332 progeny virions, thus demonstrating that recombination 
is mechanistically possible between these viruses (Mathijs et al., 2010). Importantly, RecMNV was shown 
to exhibit a viral fitness loss as evidenced by changed viral replication kinetics and smaller lysis plaque 
sizes in comparison to its two parental strains (also see Study 2). The absence of viable recombinants in 
Study 1 does thus not necessarily imply that recombination did not occur when viral coinfection was not 
impeded by superinfection exclusion. Rather, it may reflect a bias in the methodology where isolation of 
single viruses relied on plaque picking; if nascent recombinant viruses experienced a loss of replicative 
fitness similar to that of RecMNV, they may have been “overlooked” in the screening process and/or lost 
in viral replication steps. To avoid a similar bias in follow-up assays, limiting dilutions may be considered 
as an alternative for the isolation of single viruses. Future studies could further leverage population-level 
deep sequencing to analyse how the viral interference effects pinpointed here may influence the generation 
of non-viable NoV RNA recombinants (and thus ultimately influence the chances of viable recombinant 
virus generation under the application of selective pressures in vivo).  
The experimental workflow, notably the order of infection (primary infection: WU20; secondary 
infection: CW1), was not reversed in the set of experiments presented in Study 1, the assumption being that 
due to their identical growth curves, high levels of sequence similarity, and the similar input Ct values of 
the viral progenies used (results not shown), the effects would simply mirror those already observed. 
However, future confirmation of the reported interference effects might benefit from an inversion of the 
experimental workflow, the use of input viruses from viral passages with deviating infectious titres to Ct 
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values (this to account for a putative bias of interfering viral particles), and the use of other MuNoV strains 
to be juxtaposed against either WU20 or CW1.  
Novel in vitro systems for HuNoV culture (HIE cultures and BJABs as described in chapter 1.9.2) 
as well as in vivo MuNoV and/or HuNoV platforms (adult or neonatal mice (chapter 1.5.3) and zebrafish 
larvae (chapter 1.9.1), respectively) which may more closely mirror natural conditions in co- and 
superinfection assays, may further be utilised to gain a more differentiated picture of how cell coinfection, 
the second step in the recombination pathway, is accomplished by NoVs. In vivo models in particular, 
involving either the co-infection of mice with MuNoVs or that of zebrafish with HuNoVs, may provide 
insights into how host immune systems, different subsets of host cells, and also the presence of gut 
microbiota may positively or negatively impact the occurrence and outcome of NoV recombination. 
The third step, generation of a recombinant NoV genome, is typically considered to occur in a 
replicative process following a framework which combines the copy-choice model of homologous 
recombination via mid-replication RdRp template switch with an internal initiation mechanism for 
subgenomic synthesis at the highly conserved ORF1/ORF2 overlap corresponding to the junction of RdRp 
and capsid sequences (Bull et al., 2007, 2005; Ludwig-Begall et al., 2018) (discussed in chapter 2.3). 
Sequence analysis of field HuNoV strains has overwhelmingly shown the predominant recombination 
breakpoint to lie in the highly conserved ORF1/ORF2 overlap (both sequence similarity and the presence 
of a subgenomic RNA promoter at this locus suggest a similarity-assisted model of NoV recombination; 
see chapters 2.1.4 and 2.3) and both the standardized NoV nomenclature and current genotyping assays are 
designed to accommodate this recombination hotspot. However, atypical recombination breakpoints have 
also been observed (Ludwig-Begall et al., 2018). Recombination in the absence of an obvious RNA 
promoter or triggering secondary structure has been suggested to indicate that, at atypical recombination 
sites, recombination may have occurred by other mechanisms than those that induce a breakpoint in or 
around the ORF1/2 overlap (Bull et al., 2007). The possibility of non-replicative recombination, involving 
self-ligation or host-factor-mediated joining of randomly cleaved RNA strands, has been demonstrated for 
other positive-sense single-stranded RNA viruses (Büning et al., 2017; Gallei et al., 2004; Galli and Bukh, 
2014; Lowry et al., 2014), and may be considered in this context. An RdRp-independent mechanism of 
RNA recombination remains unproven for NoVs and was not examined in the context of this thesis. Future 
assays to elucidate the possibility of non-replicative NoV recombination may follow an experimental design 
used to prove RNA recombination in the absence of viral replication of pestiviruses, which allowed the 
generation of recombinant viral genomes following cotransfection of noninfected cells with various pairs 
of mutagenised nonreplicable RNA derivatives (Gallei et al., 2004).  
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By whichever way a recombinant NoV genome is ultimately generated, it is by no means a foregone 
conclusion that the process will result in a replicating recombinant NoV; recombination typically entails 
significant modifications to a single viral genome and may thus elicit a replicative fitness cost which must 
be compensated via the adaptive capacity of a nascent recombinant virus for it to survive in a viral 
population. Indeed, studies in various RNA viruses have shown that circulating recombinants probably only 
represent a subset of those that are actually generated, and are the ones that are maintained in the viral 
population after a rigorous functional selection, having bypassed this fifth and final step of successful RNA 
virus recombination (Bagaya et al., 2017; Banner and Mc Lai, 1991; Lowry et al., 2014). 
Study 2 aimed to characterise the adaptive capacity of previously in vitro generated WU20-CW1 
recombinant MuNoV RecMNV, thus investigating how the accumulation of point mutations through 
successive viral passaging may compensate for initial replicative fitness losses incurred during 
recombination processes. By comparing the replicative fitness and genetic characteristics of RecMNV 
progenies at early and late stages of an adaptation experiment, replicative fitness regain of the recombinant 
was demonstrated between viral progenies prior to and post serial in vitro passaging. Observable phenotypic 
profiles of viral fitness were associated to population-level genetic modifications. Fitness loss of RecMNV 
was thus linked to a C7245T mutation and functional VP2 (ORF3) truncation; individual and cumulative 
compensatory effects of one synonymous VP1 (OFR2) and two non-synonymous NS1/2 (ORF1) 
consensus-level mutations acquired during successive rounds of in vitro replication were demonstrated, 
suggesting that interactions of viral proteins and/or RNA secondary structures of different ORFs may play 
a role in the regulation of replicative fitness after a recombination event.  
A caveat of the Study 2 NGS approach, whereby whole consensus genome sequences of RecE and 
RecL were derived from the alignment of fragmented and trimmed MiSeq reads (circa 300 bp read length) 
via de novo assembly, is the underlying assumption for all consensus-level mutations to be present on the 
same viral genome. While viral populations (or quasispecies) typically cluster around a modal master 
sequence, it is not necessarily a given that consensus-level SNPs actually accumulate on a single viral 
genome rather than being dispersed amongst the members of the viral population. To investigate linkage or 
dispersion of consensus-level SNPs within RecE and RecL populations, it would thus be interesting to apply 
a nanopore-based sequencing approach that allows analysis of complete viral genomes and differentiation 
of viral variants (with respect to both consensus- and subconsensus level SNPs) (Reuter et al., 2015; Riaz 
et al., 2021).  
Irrespective of whether mutations are coupled on a single viral genome or are dispersed amongst 
the viral progeny, this in vitro proof-of-concept study simulated successful adaptation (genetic drift) of a 
nascent NoV population after recombination (genetic shift).  
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The model demonstrates that an initial fitness cost precipitated by genetic shift can be regained via 
genetic drift of a recombinant NoV. It serves to conceptualise how the emergence of recombinant HuNoV 
field strains, held to represent an adapted and functionally selected subset of all generated NoV 
recombinants, may be regulated by an interplay between the two evolutionary processes of recombination 
and point mutation accumulation. In vivo, putative replicative fitness costs of nascent HuNoV recombinants 
may be temporarily compensated by other advantages at the level of competitive or transmissive fitness; a 
nascent virus may regain its replicative fitness via point mutation accumulation and, having undergone a 
process of functional selection, become dominant within a viral population.  
This study may serve as a starting point for the development of in vitro or in vivo HuNoV 
recombination studies in robust culture systems and will further the identification of NoV genome segments 
specifically prone to fitness adaptation mediation. HuNoV in vivo models to study NoV recombination and 
adaptation following recombination may involve infection of zebrafish (as described above). Further 
studies concerning the adaptation of a MuNoV recombinant to in vivo conditions, may feasibly build on 
prior work performed by Mathijs et al., involving the infection of Balb/cByJ mice with RecMNV; the 
RecMNV populations resulting from the 48- and 72-hour in vivo infections (Mathijs et al., 2016) merit 
attention with regard to population-level genomic changes putatively incurred during several rounds of viral 
replication  in an immunocompetent host.  
The knowledge gained via in vitro and in vivo studies involving various model systems will provide 
a more complete picture of the interplay between NoV genetic shift and drift and will provide information 
for the effective detection and screening of emerging recombinant NoV strains. 
In conclusion, this thesis aimed to provide a deeper understanding of the steps, drivers and 
constraints of NoV recombination via implementation of the in vitro MuNoV model. It served to provide a 
comprehensive overview of the recombination checkpoints to be bypassed and, in investigating both 
superinfection exclusion as well as functional selection, provided novel insights into prerequisite processes 
both before and after the generation of a recombinant NoV genome.  
It would seem remiss to end this thesis without at least a nod to the father of evolution and I close 
with a quote by Charles Darwin who wrote, in a statement particularly apt to NoVs, that: 
“It is not the strongest of the species that survives, nor the most intelligent that survives. It is the 
one that is the most adaptable to change.”
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